Expression	O
of	O
interferon	B-protein
consensus	I-protein
sequence	I-protein
binding	I-protein
protein	I-protein
induces	O
potent	O
immunity	O
against	O
BCR/ABL-induced	O
leukemia	O
.	O

Mice	O
deficient	O
in	O
the	O
interferon	B-protein
consensus	I-protein
sequence	I-protein
binding	I-protein
protein	I-protein
(	O
ICSBP	B-protein
)	O
develop	O
a	O
disease	O
resembling	O
chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
,	O
which	O
in	O
humans	O
is	O
caused	O
by	O
the	O
BCR/ABL	B-protein
oncoprotein	I-protein
.	O

Interferon-alpha	B-protein
(	O
IFN-alpha	B-protein
)	O
induces	O
ICSBP	B-protein
expression	O
and	O
is	O
an	O
effective	O
therapy	O
for	O
CML	O
.	O

This	O
study	O
examined	O
whether	O
enforced	O
expression	O
of	O
ICSBP	B-protein
might	O
antagonize	O
BCR/ABL-induced	O
leukemia	O
;	O
results	O
demonstrated	O
that	O
ICSBP-modified	B-cell_type
cells	I-cell_type
generated	O
a	O
protective	O
CD8	O
(	O
+	O
)	O
cytotoxic	O
T-cell	O
response	O
against	O
BCR/ABL-transformed	B-cell_type
BaF3	I-cell_type
cells	I-cell_type
in	O
a	O
murine	O
leukemia	O
model	O
.	O

ICSBP	B-protein
expression	O
represents	O
a	O
novel	O
means	O
of	O
stimulating	O
a	O
host	O
immune	O
response	O
to	O
BCR/ABL	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
and	O
a	O
potential	O
strategy	O
for	O
immunotherapy	O
of	O
CML	O
.	O

(	O
Blood.	O
2001	O
;	O
97	O
:	O
3491-3497	O
)	O

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

IMMUNOBIOLOGY	NULL
Expression	NULL
of	NULL
interferon	NULL
consensus	NULL
sequence	NULL
binding	NULL
protein	NULL
induces	NULL
potent	NULL
immunity	NULL
against	NULL
BCR/ABL-induced	NULL
leukemia	NULL
Ming	NULL
Deng	NULL
and	NULL
George	NULL
Q.	NULL
Daley	NULL
Mice	NULL
deficient	NULL
in	NULL
the	NULL
interferon	NULL
consensus	NULL
sequence	NULL
binding	NULL
protein	NULL
(	NULL
ICSBP	NULL
)	NULL
develop	NULL
a	NULL
disease	NULL
resembling	NULL
chronic	NULL
myeloid	NULL
leukemia	NULL
(	NULL
CML	NULL
)	NULL
,	NULL
which	NULL
in	NULL
humans	NULL
is	NULL
caused	NULL
by	NULL
the	NULL
BCR/ABL	NULL
oncoprotein	NULL
.	NULL

Interferon-	NULL
«	NULL
(	NULL
IFN-	NULL
«	NULL
)	NULL
induces	NULL
ICSBP	NULL
expression	NULL
and	NULL
is	NULL
an	NULL
effective	NULL
therapy	NULL
for	NULL
CML	NULL
.	NULL

This	NULL
study	NULL
examined	NULL
whether	NULL
enforced	NULL
expression	NULL
of	NULL
ICSBP	NULL
might	NULL
antagonize	NULL
BCR/ABL-induced	NULL
leukemia	NULL
;	NULL
results	NULL
demonstrated	NULL
that	NULL
ICSBP-modified	NULL
cells	NULL
generated	NULL
a	NULL
protective	NULL
CD8+	NULL
cytotoxic	NULL
T-cell	NULL
response	NULL
against	NULL
BCR/ABL-transformed	NULL
BaF3	NULL
cells	NULL
in	NULL
a	NULL
murine	NULL
leukemia	NULL
model	NULL
.	NULL

ICSBP	NULL
expression	NULL
represents	NULL
a	NULL
novel	NULL
means	NULL
of	NULL
stimulating	NULL
a	NULL
host	NULL
immune	NULL
response	NULL
to	NULL
BCR/ABL+®	NULL
leukemia	NULL
cells	NULL
and	NULL
a	NULL
potential	NULL
strategy	NULL
for	NULL
immunotherapy	NULL
of	NULL
CML	NULL
.	NULL

(	NULL
Blood	NULL
.	NULL

2001	NULL
;	NULL
97:3491-3497	NULL
)	NULL
©2001	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
Introduction	NULL
Chronic	NULL
myeloid	NULL
leukemia	NULL
(	NULL
CML	NULL
)	NULL
is	NULL
a	NULL
hematopoietic	NULL
stem	NULL
cell	NULL
malignancy	NULL
caused	NULL
by	NULL
the	NULL
BCR/ABL	NULL
oncoprotein	NULL
.	NULL

The	NULL
disease	NULL
is	NULL
invariably	NULL
fatal	NULL
but	NULL
can	NULL
be	NULL
cured	NULL
by	NULL
allogeneic	NULL
bone	NULL
marrow	NULL
transplantation	NULL
(	NULL
BMT	NULL
)	NULL
.	NULL

This	NULL
highly	NULL
morbid	NULL
therapy	NULL
serves	NULL
only	NULL
a	NULL
minority	NULL
of	NULL
patients	NULL
,	NULL
primarily	NULL
younger	NULL
individuals	NULL
with	NULL
an	NULL
HLA-matched	NULL
donor	NULL
.	NULL
``	NULL

The	NULL
remainder	NULL
are	NULL
typically	NULL
treated	NULL
with	NULL
interferon-	NULL
«	NULL
(	NULL
IFN-	NULL
«	NULL
)	NULL
,	NULL
which	NULL
induces	NULL
complete	NULL
cytogenetic	NULL
remission	NULL
,	NULL
delays	NULL
blast	NULL
crisis	NULL
,	NULL
and	NULL
prolongs	NULL
survival	NULL
in	NULL
a	NULL
significant	NULL
percentage	NULL
of	NULL
patients	NULL
.	NULL
``	NULL

IFN-	NULL
«	NULL
selectively	NULL
suppresses	NULL
BCR/ABL	NULL
*	NULL
cells	NULL
in	NULL
the	NULL
bone	NULL
marrow	NULL
by	NULL
restoring	NULL
defective	NULL
integrin	NULL
function	NULL
and	NULL
apoptosis	NULL
in	NULL
CML	NULL
progenitors	NULL
,	NULL
``	NULL
and	NULL
may	NULL
down-regulate	NULL
BCR/ABL	NULL
transcrip-tion	NULL
.	NULL

*	NULL
Although	NULL
some	NULL
patients	NULL
treated	NULL
with	NULL
IFN	NULL
sustain	NULL
complete	NULL
cytogenetic	NULL
remission	NULL
,	NULL
persistence	NULL
of	NULL
BCR/ABL*	NULL
clones	NULL
can	NULL
be	NULL
demonstrated	NULL
by	NULL
reverse	NULL
transcription-polymerase	NULL
chain	NULL
reaction	NULL
(	NULL
RT-PCR	NULL
)	NULL
,	NULL
arguing	NULL
that	NULL
leukemia	NULL
cells	NULL
remain	NULL
dormant	NULL
.	NULL
``	NULL

''	NULL
IFN-	NULL
«	NULL
potentiates	NULL
the	NULL
development	NULL
of	NULL
antileukemic	NULL
natural	NULL
killer	NULL
(	NULL
NK	NULL
)	NULL
cells	NULL
in	NULL
patients	NULL
with	NULL
CML	NULL
,	NULL
and	NULL
some	NULL
IFN-treated	NULL
patients	NULL
in	NULL
long-term	NULL
remission	NULL
have	NULL
demonstrable	NULL
cellular	NULL
immunoreactivity	NULL
against	NULL
BCR/ABL	NULL
sequences	NULL
.	NULL
``	NULL

Specific	NULL
T-cell	NULL
immunity	NULL
against	NULL
an	NULL
epitope	NULL
on	NULL
the	NULL
proteinase	NULL
3	NULL
component	NULL
of	NULL
neutrophil	NULL
granules	NULL
has	NULL
recently	NULL
been	NULL
demonstrated	NULL
in	NULL
patients	NULL
who	NULL
have	NULL
sustained	NULL
a	NULL
complete	NULL
cytogenetic	NULL
remission	NULL
on	NULL
IFN-	NULL
«	NULL
.	NULL
'	NULL

''	NULL
These	NULL
observations	NULL
suggest	NULL
that	NULL
IFN	NULL
encourages	NULL
active	NULL
suppression	NULL
of	NULL
leukemic	NULL
clones	NULL
by	NULL
the	NULL
immune	NULL
system	NULL
,	NULL
but	NULL
the	NULL
precise	NULL
molecular	NULL
mechanisms	NULL
by	NULL
which	NULL
IFN	NULL
modulates	NULL
immunity	NULL
in	NULL
patients	NULL
with	NULL
CML	NULL
have	NULL
not	NULL
been	NULL
defined	NULL
.	NULL

Treatment	NULL
with	NULL
IFN	NULL
induces	NULL
JAK-STAT1/2	NULL
signaling	NULL
and	NULL
activation	NULL
of	NULL
transcription	NULL
factors	NULL
called	NULL
interferon	NULL
regulatory	NULL
factors	NULL
(	NULL
IRFs	NULL
)	NULL
.	NULL

IRFs	NULL
have	NULL
homologous	NULL
DNA	NULL
binding	NULL
domains	NULL
that	NULL
recognize	NULL
a	NULL
consensus	NULL
sequence	NULL
present	NULL
in	NULL
both	NULL
IFNs	NULL
and	NULL
IFN-inducible	NULL
genes	NULL
.	NULL

IRFs	NULL
modulate	NULL
antiviral	NULL
actions	NULL
,	NULL
cell	NULL
proliferation	NULL
,	NULL
apoptosis	NULL
,	NULL
and	NULL
integrin	NULL
function	NULL
and	NULL
are	NULL
also	NULL
important	NULL
in	NULL
regulating	NULL
hematopoiesis	NULL
and	NULL
immune	NULL
responses	NULL
.	NULL
``	NULL

Genetic	NULL
disruption	NULL
of	NULL
IRF-1	NULL
or	NULL
IRF-2	NULL
results	NULL
in	NULL
poor	NULL
responses	NULL
to	NULL
IFN-	NULL
«	NULL
,	NULL
-B	NULL
,	NULL
and	NULL
-y	NULL
and	NULL
abnormal	NULL
lymphocyte	NULL
homeostasis	NULL
.	NULL

'*	NULL
Another	NULL
IRF	NULL
family	NULL
member	NULL
,	NULL
the	NULL
interferon	NULL
consensus	NULL
sequence	NULL
binding	NULL
protein	NULL
(	NULL
ICSBP	NULL
)	NULL
was	NULL
identified	NULL
as	NULL
a	NULL
conditional	NULL
regulator	NULL
of	NULL
IFN-inducible	NULL
transcription	NULL
.	NULL
``	NULL

ICSBP	NULL
expression	NULL
is	NULL
primarily	NULL
restricted	NULL
to	NULL
hematopoietic	NULL
tissues	NULL
,	NULL
where	NULL
it	NULL
binds	NULL
to	NULL
and	NULL
functionally	NULL
cooperates	NULL
with	NULL
PU.1	NULL
,	NULL
an	NULL
ETS	NULL
transcription	NULL
factor	NULL
involved	NULL
in	NULL
regulating	NULL
gene	NULL
expression	NULL
in	NULL
myeloid	NULL
and	NULL
lymphoid	NULL
cells	NULL
.	NULL
``	NULL

''	NULL
``	NULL
Gene	NULL
knock-out	NULL
of	NULL
ICBSP	NULL
induces	NULL
a	NULL
CML-like	NULL
disease	NULL
in	NULL
mice	NULL
.	NULL

*	NULL
``	NULL
Myeloid	NULL
cells	NULL
derived	NULL
from	NULL
ICSBP-deficient	NULL
mice	NULL
exhibit	NULL
reduced	NULL
spontaneous	NULL
apoptosis	NULL
and	NULL
a	NULL
significant	NULL
decrease	NULL
in	NULL
sensitivity	NULL
to	NULL
apoptosis	NULL
induced	NULL
by	NULL
DNA	NULL
damage	NULL
.	NULL
``	NULL

In	NULL
addition	NULL
,	NULL
ICSBP-~-	NULL
hematopoietic	NULL
progenitors	NULL
are	NULL
hypersensitive	NULL
to	NULL
cytokine	NULL
stimulation	NULL
by	NULL
interleukin	NULL
(	NULL
IL	NULL
)	NULL
-3	NULL
,	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
GM-CSF	NULL
)	NULL
,	NULL
and	NULL
granulocyte	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
G-CSF	NULL
)	NULL
.	NULL
``	NULL

Because	NULL
the	NULL
myeloproliferative	NULL
disease	NULL
observed	NULL
in	NULL
ICSBP-deficient	NULL
mice	NULL
resembled	NULL
human	NULL
CML	NULL
,	NULL
expression	NULL
patterns	NULL
of	NULL
ICSBP	NULL
were	NULL
examined	NULL
in	NULL
patients	NULL
with	NULL
CML	NULL
.	NULL

ICSBP	NULL
transcript	NULL
levels	NULL
were	NULL
depressed	NULL
in	NULL
the	NULL
leukemic	NULL
blood	NULL
cells	NULL
of	NULL
patients	NULL
with	NULL
CML	NULL
and	NULL
restored	NULL
in	NULL
patients	NULL
successfully	NULL
treated	NULL
with	NULL
IFN-	NULL
«	NULL
.	NULL

*4	NULL
Retroviral	NULL
transduction	NULL
of	NULL
mouse	NULL
bone	NULL
marrow	NULL
with	NULL
BCR/ABL	NULL
resulted	NULL
in	NULL
a	NULL
marked	NULL
decrease	NULL
in	NULL
ICSBP	NULL
expression	NULL
,	NULL
whereas	NULL
forced	NULL
overexpression	NULL
of	NULL
human	NULL
ICSBP	NULL
attentuated	NULL
BCR/ABL-induced	NULL
leukemia	NULL
in	NULL
a	NULL
murine	NULL
model	NULL
.	NULL
``	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
ICSBP	NULL
might	NULL
act	NULL
as	NULL
a	NULL
tumor	NULL
suppressor	NULL
gene	NULL
in	NULL
hematopoietic	NULL
cells	NULL
.	NULL

Various	NULL
studies	NULL
have	NULL
determined	NULL
that	NULL
ICSBP	NULL
also	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
modulating	NULL
the	NULL
immune	NULL
response	NULL
by	NULL
influencing	NULL
the	NULL
differentiation	NULL
and	NULL
maturation	NULL
of	NULL
immune	NULL
cells	NULL
and	NULL
by	NULL
affecting	NULL
cytokine	NULL
expres-sion	NULL
.	NULL

``	NULL
*	NULL
``	NULL
``	NULL
ICSBP-deficient	NULL
mice	NULL
have	NULL
defective	NULL
production	NULL
of	NULL
IL-12	NULL
and	NULL
IFN-y	NULL
,	NULL
an	NULL
impaired	NULL
Thl1	NULL
immune	NULL
response	NULL
,	NULL
and	NULL
enhanced	NULL
susceptibility	NULL
to	NULL
intracellular	NULL
pathogens.2	NULL
``	NULL
``	NULL
We	NULL
hypothesized	NULL
that	NULL
ICSBP	NULL
might	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
ability	NULL
of	NULL
IFN-	NULL
«	NULL
to	NULL
antagonize	NULL
From	NULL
the	NULL
Whitehead	NULL
Institute	NULL
,	NULL
Cambridge	NULL
,	NULL
Massachusetts	NULL
,	NULL
and	NULL
Division	NULL
of	NULL
Hematology/Oncology	NULL
,	NULL
Massachusetts	NULL
General	NULL
Hospital	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
.	NULL

Submitted	NULL
October	NULL
3	NULL
,	NULL
2000	NULL
;	NULL
accepted	NULL
January	NULL
30	NULL
,	NULL
2001	NULL
.	NULL

Supported	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
National	NULL
Cancer	NULL
Institute	NULL
CA76418	NULL
and	NULL
CA86991	NULL
(	NULL
G.QD	NULL
.	NULL
)	NULL

.	NULL

G.QD	NULL
.	NULL

is	NULL
a	NULL
recipient	NULL
of	NULL
the	NULL
Burroughs	NULL
Wellcome	NULL
Career	NULL
Development	NULL
Award	NULL
and	NULL
is	NULL
the	NULL
Birnbaum	NULL
Scholar	NULL
of	NULL
the	NULL
Leukemia	NULL
and	NULL
Lymphoma	NULL
Society	NULL
of	NULL
America	NULL
.	NULL

M.D	NULL
.	NULL

is	NULL
a	NULL
recipient	NULL
of	NULL
a	NULL
fellowship	NULL
from	NULL
the	NULL
BLOOD	NULL
,	NULL
1	NULL
JUNE	NULL
2001	NULL
«	NULL
VOLUME	NULL
97	NULL
,	NULL
NUMBER	NULL
11	NULL
Cancer	NULL
Research	NULL
Institute	NULL
(	NULL
New	NULL
York	NULL
)	NULL
.	NULL

Reprints	NULL
:	NULL
George	NULL
Q.	NULL
Daley	NULL
,	NULL
Whitehead	NULL
Institute	NULL
,	NULL
9	NULL
Cambridge	NULL
Center	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
02142	NULL
;	NULL
e-mail	NULL
:	NULL
daley	NULL
@	NULL
wi.mit.edu	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

Therefore	NULL
,	NULL
and	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
,	NULL
this	NULL
article	NULL
is	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

section	NULL
1734	NULL
.	NULL

©2001	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
3491	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

3492	NULL
-	NULL
DENG	NULL
and	NULL
DALEY	NULL
BCR/ABL	NULL
transformation	NULL
through	NULL
immune	NULL
suppression	NULL
.	NULL

We	NULL
tested	NULL
whether	NULL
ectopic	NULL
overexpression	NULL
of	NULL
murine	NULL
ICSBP	NULL
could	NULL
antagonize	NULL
BCR/ABL-induced	NULL
leukemia	NULL
using	NULL
a	NULL
simple	NULL
model	NULL
system	NULL
and	NULL
have	NULL
demonstrated	NULL
that	NULL
expression	NULL
of	NULL
ICSBP	NULL
in	NULL
the	NULL
BCR/ABL-transformed	NULL
BaF3	NULL
cell	NULL
line	NULL
completely	NULL
abolished	NULL
its	NULL
leukemogenic-ity	NULL
in	NULL
an	NULL
immunocompetent	NULL
host	NULL
.	NULL

Furthermore	NULL
,	NULL
mice	NULL
that	NULL
survived	NULL
the	NULL
challenge	NULL
with	NULL
ICSBP-modified	NULL
leukemia	NULL
cells	NULL
gained	NULL
long-lasting	NULL
immunity	NULL
against	NULL
parental	NULL
leukemia	NULL
cells	NULL
.	NULL

This	NULL
immune	NULL
rejection	NULL
was	NULL
associated	NULL
with	NULL
T-cell-mediated	NULL
reactivity	NULL
against	NULL
cell	NULL
surface	NULL
antigens	NULL
specific	NULL
to	NULL
BCR/ABL-transformed	NULL
cells	NULL
.	NULL

The	NULL
immune-mediated	NULL
rejection	NULL
of	NULL
leukemic	NULL
cells	NULL
induced	NULL
by	NULL
ICSBP	NULL
is	NULL
rapid	NULL
,	NULL
potent	NULL
,	NULL
and	NULL
effective	NULL
against	NULL
pre-established	NULL
disease	NULL
,	NULL
suggesting	NULL
that	NULL
ectopic	NULL
ICSBP	NULL
expression	NULL
may	NULL
provide	NULL
a	NULL
novel	NULL
immuno-therapeutic	NULL
strategy	NULL
for	NULL
BCR/ABL	NULL
*	NULL
leukemia	NULL
patients	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Animals	NULL
Six-	NULL
to	NULL
12-week-old	NULL
female	NULL
Balb/c	NULL
mice	NULL
were	NULL
purchased	NULL
from	NULL
Jackson	NULL
Laboratories	NULL
(	NULL
Bar	NULL
Harbor	NULL
,	NULL
ME	NULL
)	NULL
.	NULL

Rag-1~	NULL
and	NULL
nonobese	NULL
diabetic/severe	NULL
combined	NULL
immunodeficiency	NULL
(	NULL
NOD/SCID	NULL
)	NULL
mice	NULL
(	NULL
Jackson	NULL
Laboratories	NULL
)	NULL
were	NULL
obtained	NULL
at	NULL
6	NULL
weeks	NULL
old	NULL
and	NULL
maintained	NULL
in	NULL
sterile	NULL
conditions	NULL
.	NULL

Cell	NULL
lines	NULL
,	NULL
transfection	NULL
,	NULL
and	NULL
infection	NULL
BaF3	NULL
,	NULL
a	NULL
murine	NULL
pro-B	NULL
cell	NULL
line	NULL
,	NULL
``	NULL
``	NULL
was	NULL
maintained	NULL
in	NULL
complete	NULL
RPMI	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
conditioned	NULL
medium	NULL
from	NULL
WEHI-3B	NULL
cells	NULL
,	NULL
as	NULL
a	NULL
source	NULL
of	NULL
IL-3	NULL
.	NULL

Mycoplasma	NULL
infection	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
alter	NULL
the	NULL
tumorigenicity	NULL
of	NULL
cell	NULL
lines	NULL
and	NULL
the	NULL
corresponding	NULL
host	NULL
immune	NULL
responses	NULL
.	NULL
``	NULL

We	NULL
have	NULL
confirmed	NULL
that	NULL
the	NULL
BaF3	NULL
cell	NULL
lines	NULL
we	NULL
used	NULL
in	NULL
our	NULL
experiments	NULL
were	NULL
Mycoplasma	NULL
free	NULL
by	NULL
both	NULL
PCR	NULL
and	NULL
antibody	NULL
detection	NULL
.	NULL

ICSBP	NULL
and	NULL
BCR/ABL	NULL
constructs	NULL
were	NULL
introduced	NULL
into	NULL
the	NULL
cells	NULL
by	NULL
electroporation	NULL
using	NULL
vectors	NULL
pCXN2-ICSBP	NULL
(	NULL
kindly	NULL
provided	NULL
by	NULL
Dr	NULL
Keiko	NULL
Ozato	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
)	NULL
and	NULL
MSCV-BCR/ABL-PAC	NULL
.	NULL

Cells	NULL
were	NULL
selected	NULL
in	NULL
2	NULL
pg/mL	NULL
puromycin	NULL
for	NULL
BCR/ABL	NULL
and	NULL
2	NULL
mg/mL	NULL
G418	NULL
for	NULL
ICSBP	NULL
to	NULL
achieve	NULL
stable	NULL
expression	NULL
.	NULL

Moloney	NULL
murine	NULL
sarcoma	NULL
virus	NULL
(	NULL
M-MSV	NULL
)	NULL
-transformed	NULL
3T3	NULL
cells	NULL
and	NULL
Lewis	NULL
lung	NULL
carcinoma	NULL
cells	NULL
were	NULL
obtained	NULL
form	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
(	NULL
ATCC	NULL
,	NULL
Manassas	NULL
,	NULL
VA	NULL
)	NULL
and	NULL
cultured	NULL
in	NULL
RPMI	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
.	NULL

Immunoblotting	NULL
analysis	NULL
and	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
Cells	NULL
were	NULL
lysed	NULL
in	NULL
buffer	NULL
containing	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
20	NULL
mM	NULL
Tris	NULL
(	NULL
pH	NULL
7.4	NULL
)	NULL
,	NULL
10	NULL
mM	NULL
NaF	NULL
,	NULL
1	NULL
mM	NULL
ZnCl	NULL
;	NULL
,	NULL
1	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
and	NULL
1	NULL
%	NULL
NP-40	NULL
.	NULL

Total	NULL
proteins	NULL
(	NULL
40	NULL
pg	NULL
)	NULL
were	NULL
separated	NULL
by	NULL
sodium	NULL
dodecyl	NULL
sulfate-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
(	NULL
10	NULL
%	NULL
)	NULL
and	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
membrane	NULL
.	NULL

Both	NULL
polyclonal	NULL
«	NULL
-ICSBP	NULL
(	NULL
kindly	NULL
provided	NULL
by	NULL
Dr	NULL
Keiko	NULL
Ozato	NULL
)	NULL
and	NULL
«	NULL
-ABL	NULL
antibodies	NULL
were	NULL
used	NULL
at	NULL
1:5000	NULL
dilution	NULL
.	NULL

Horseradish	NULL
peroxi-dase	NULL
(	NULL
HRP	NULL
)	NULL
-conjugated	NULL
goat	NULL
antirabbit	NULL
IgG	NULL
secondary	NULL
antibody	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
and	NULL
enhanced	NULL
chemoluminescence	NULL
(	NULL
ECL	NULL
)	NULL
were	NULL
used	NULL
to	NULL
detect	NULL
protein	NULL
expression	NULL
.	NULL

Conditioned	NULL
media	NULL
from	NULL
BaF3	NULL
and	NULL
its	NULL
derived	NULL
cell	NULL
lines	NULL
were	NULL
collected	NULL
and	NULL
concentrated	NULL
with	NULL
Centricon	NULL
filters	NULL
(	NULL
YM-10	NULL
;	NULL
Millipore	NULL
,	NULL
Bedford	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

Enzyme-linked	NULL
immunosorbent	NULL
assays	NULL
(	NULL
ELISAs	NULL
)	NULL
for	NULL
IL-12	NULL
,	NULL
IFN-y	NULL
,	NULL
and	NULL
GM-CSF	NULL
were	NULL
carried	NULL
out	NULL
using	NULL
Quan-tikine	NULL
immunoassay	NULL
reagents	NULL
according	NULL
to	NULL
manufacturer	NULL
's	NULL
protocols	NULL
(	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
,	NULL
Minneapolis	NULL
,	NULL
MN	NULL
)	NULL
.	NULL

CD8/CD4	NULL
fractionation	NULL
The	NULL
CD8+	NULL
or	NULL
CD4*	NULL
cells	NULL
were	NULL
purified	NULL
or	NULL
depleted	NULL
from	NULL
single	NULL
spleen	NULL
cell	NULL
suspensions	NULL
using	NULL
Dynalbeads	NULL
conjugated	NULL
with	NULL
CD8	NULL
(	NULL
Lyt2	NULL
)	NULL
or	NULL
CD4	NULL
(	NULL
L3T4	NULL
)	NULL
antibodies	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
protocol	NULL
(	NULL
Dynal	NULL
,	NULL
Lake	NULL
Success	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

The	NULL
purity	NULL
of	NULL
positively	NULL
isolated	NULL
cells	NULL
and	NULL
the	NULL
efficiency	NULL
of	NULL
negative	NULL
depletions	NULL
were	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometric	NULL
analysis	NULL
.	NULL

BLOOD	NULL
,	NULL
1	NULL
JUNE	NULL
2001	NULL
»	NULL
VOLUME	NULL
97	NULL
,	NULL
NUMBER	NULL
11	NULL
Flow	NULL
cytometric	NULL
analysis	NULL
Cells	NULL
(	NULL
10	NULL
)	NULL
were	NULL
resuspended	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
and	NULL
incubated	NULL
with	NULL
phycoerythrin	NULL
(	NULL
PE	NULL
)	NULL
-conjugated	NULL
antibodies	NULL
against	NULL
major	NULL
histocompatibility	NULL
complex	NULL
(	NULL
MHC	NULL
)	NULL
class	NULL
I	NULL
,	NULL
MHC	NULL
class	NULL
II	NULL
,	NULL
CD8	NULL
,	NULL
and	NULL
CD4	NULL
.	NULL

For	NULL
B7-1	NULL
and	NULL
B7-2	NULL
detection	NULL
,	NULL
purified	NULL
primary	NULL
antibodies	NULL
were	NULL
used	NULL
,	NULL
followed	NULL
by	NULL
a	NULL
biotinylated	NULL
secondary	NULL
antibody	NULL
and	NULL
PE-conjugated	NULL
streptavi-din	NULL
staining	NULL
.	NULL

All	NULL
antibodies	NULL
were	NULL
purchased	NULL
from	NULL
Pharmingen	NULL
(	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
and	NULL
cells	NULL
were	NULL
analyzed	NULL
on	NULL
the	NULL
Becton	NULL
Dickinson	NULL
FACSCalibur	NULL
immunocytometry	NULL
system	NULL
(	NULL
San	NULL
Jose	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Mice	NULL
injection	NULL
and	NULL
analyses	NULL
The	NULL
BaF3-derived	NULL
cells	NULL
were	NULL
injected	NULL
intravenously	NULL
into	NULL
mouse	NULL
lateral	NULL
tail	NULL
vein	NULL
.	NULL

Mice	NULL
were	NULL
closely	NULL
monitored	NULL
and	NULL
were	NULL
killed	NULL
if	NULL
moribund	NULL
.	NULL

Peripheral	NULL
blood	NULL
,	NULL
spleen	NULL
,	NULL
and	NULL
bone	NULL
marrow	NULL
samples	NULL
were	NULL
subsequently	NULL
isolated	NULL
from	NULL
the	NULL
mice	NULL
for	NULL
cell	NULL
morphology	NULL
analysis	NULL
by	NULL
staining	NULL
centrifuged	NULL
cells	NULL
with	NULL
the	NULL
Hema	NULL
3	NULL
stain	NULL
set	NULL
(	NULL
Biochemical	NULL
Sciences	NULL
,	NULL
Swedesboro	NULL
,	NULL
NJ	NULL
)	NULL
.	NULL

Genomic	NULL
DNA	NULL
and	NULL
messenger	NULL
RNA	NULL
(	NULL
mRNA	NULL
)	NULL
were	NULL
also	NULL
isolated	NULL
using	NULL
DNA	NULL
extraction	NULL
reagent	NULL
(	NULL
Qiagen	NULL
,	NULL
Valencia	NULL
,	NULL
CA	NULL
)	NULL
and	NULL
RNA	NULL
STAT-60	NULL
reagent	NULL
(	NULL
Tel-Test	NULL
``	NULL
B	NULL
,	NULL
``	NULL
Friendswood	NULL
,	NULL
TX	NULL
)	NULL
.	NULL

Cell-mediated	NULL
cytotoxicity	NULL
and	NULL
cold	NULL
target	NULL
inhibition	NULL
assays	NULL
Fresh	NULL
spleen	NULL
cells	NULL
were	NULL
isolated	NULL
from	NULL
either	NULL
naive	NULL
or	NULL
Ba-P210-ICSBP	NULL
immunized	NULL
mice	NULL
2	NULL
weeks	NULL
after	NULL
the	NULL
immunization	NULL
and	NULL
were	NULL
cultured	NULL
in	NULL
complete	NULL
K	NULL
medium	NULL
(	NULL
RPMI	NULL
1640	NULL
,	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
with	NULL
50pM	NULL
B-mercaptocethanol	NULL
,	NULL
1	NULL
mM	NULL
nonessential	NULL
amino	NULL
acids	NULL
,	NULL
10	NULL
mM	NULL
sodium	NULL
pyruvate	NULL
;	NULL
Gibco	NULL
BRL	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

Irradiated	NULL
Ba-P210-ICSBP	NULL
cells	NULL
(	NULL
20	NULL
000	NULL
cGy	NULL
)	NULL
were	NULL
cocultured	NULL
with	NULL
the	NULL
spleen	NULL
cells	NULL
for	NULL
6	NULL
days	NULL
.	NULL

On	NULL
day	NULL
7	NULL
,	NULL
cytotoxic	NULL
activities	NULL
of	NULL
stimulated	NULL
cells	NULL
were	NULL
determined	NULL
in	NULL
a	NULL
standard	NULL
4-hour	NULL
``	NULL
Cr-release	NULL
assay	NULL
with	NULL
the	NULL
following	NULL
modifications	NULL
.	NULL
``	NULL

Five	NULL
thousand	NULL
target	NULL
cells	NULL
were	NULL
labeled	NULL
with	NULL
100.Ci	NULL
sodium	NULL
[	NULL
**Cr	NULL
]	NULL
chromate	NULL
and	NULL
incubated	NULL
for	NULL
1	NULL
hour	NULL
before	NULL
use	NULL
.	NULL

Cytotoxic	NULL
T	NULL
lymphocytes	NULL
(	NULL
CTLs	NULL
)	NULL
were	NULL
added	NULL
to	NULL
achieve	NULL
different	NULL
effector-target	NULL
ratios	NULL
of	NULL
5:1	NULL
,	NULL
25:1	NULL
,	NULL
50:1	NULL
,	NULL
and	NULL
100:1	NULL
.	NULL

Specific	NULL
lysis	NULL
was	NULL
determined	NULL
as	NULL
follows	NULL
:	NULL
percent	NULL
specific	NULL
release	NULL
=	NULL
100	NULL
X	NULL
(	NULL
release	NULL
by	NULL
effector	NULL
cells	NULL
-	NULL
spontaneous	NULL
release	NULL
)	NULL
/	NULL
(	NULL
maximum	NULL
release	NULL
-	NULL
spontaneous	NULL
release	NULL
)	NULL
.	NULL

Spontaneous	NULL
release	NULL
was	NULL
less	NULL
than	NULL
20	NULL
%	NULL
of	NULL
maximum	NULL
release	NULL
in	NULL
all	NULL
experiments	NULL
.	NULL

Competitive	NULL
inhibition	NULL
studies	NULL
were	NULL
carried	NULL
out	NULL
by	NULL
measuring	NULL
the	NULL
specific	NULL
lysis	NULL
of	NULL
'Cr-labeled	NULL
target	NULL
cells	NULL
by	NULL
a	NULL
fixed	NULL
number	NULL
of	NULL
effector	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
various	NULL
number	NULL
of	NULL
unlabeled	NULL
tester	NULL
cells	NULL
.	NULL

Unlabeled	NULL
cells	NULL
were	NULL
added	NULL
to	NULL
the	NULL
reaction	NULL
wells	NULL
at	NULL
the	NULL
same	NULL
time	NULL
as	NULL
the	NULL
**Cr-loaded	NULL
target	NULL
cells	NULL
.	NULL

Results	NULL
Expression	NULL
of	NULL
ICSBP	NULL
did	NULL
not	NULL
alter	NULL
BCR/ABL	NULL
transformation	NULL
of	NULL
BaF3	NULL
cells	NULL
in	NULL
vitro	NULL
The	NULL
IL-3-dependent	NULL
murine	NULL
bone	NULL
marrow-derived	NULL
cell	NULL
line	NULL
BaF3	NULL
lacks	NULL
endogenous	NULL
ICSBP	NULL
expression	NULL
and	NULL
is	NULL
readily	NULL
transformed	NULL
by	NULL
BCR/ABL	NULL
,	NULL
and	NULL
therefore	NULL
serves	NULL
as	NULL
a	NULL
model	NULL
to	NULL
investigate	NULL
the	NULL
effect	NULL
of	NULL
ectopically	NULL
expressed	NULL
ICSBP	NULL
on	NULL
BCR/ABL-induced	NULL
leukemia	NULL
.	NULL

We	NULL
created	NULL
the	NULL
Ba-P210	NULL
cell	NULL
line	NULL
by	NULL
stably	NULL
transfecting	NULL
BaF3	NULL
cells	NULL
with	NULL
a	NULL
BCR/ABL	NULL
vector	NULL
.	NULL

Subsequently	NULL
,	NULL
ICSBP	NULL
was	NULL
transfected	NULL
into	NULL
Ba-P210	NULL
cells	NULL
to	NULL
generate	NULL
the	NULL
Ba-P210-ICSBP	NULL
cell	NULL
line	NULL
.	NULL

Both	NULL
cell	NULL
lines	NULL
expressed	NULL
a	NULL
high	NULL
level	NULL
of	NULL
the	NULL
BCR/ABL	NULL
(	NULL
P210	NULL
)	NULL
oncoprotein	NULL
;	NULL
Ba-P210-ICSBP	NULL
also	NULL
expressed	NULL
a	NULL
high	NULL
level	NULL
of	NULL
murine	NULL
ICSBP	NULL
(	NULL
Figure	NULL
1A	NULL
)	NULL
.	NULL

The	NULL
expression	NULL
level	NULL
of	NULL
ICSBP	NULL
in	NULL
Ba-P210-ICSBP	NULL
cells	NULL
was	NULL
comparable	NULL
to	NULL
the	NULL
endogenous	NULL
ICSBP	NULL
level	NULL
in	NULL
the	NULL
human	NULL
lymphoid	NULL
cell	NULL
lines	NULL
Namalwa	NULL
,	NULL
Daudi	NULL
,	NULL
and	NULL
Ramos	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
BCR/ABL	NULL
transforms	NULL
BaF3	NULL
cells	NULL
to	NULL
IL-3	NULL
independence	NULL
and	NULL
resistance	NULL
to	NULL
apoptosis	NULL
induced	NULL
by	NULL
y-irradia-tion	NULL
.	NULL
``	NULL

There	NULL
was	NULL
no	NULL
obvious	NULL
effect	NULL
of	NULL
ICSBP	NULL
expression	NULL
on	NULL
the	NULL
morphology	NULL
or	NULL
proliferation	NULL
characteristics	NULL
of	NULL
the	NULL
BCR/ABL-transformed	NULL
BaF3	NULL
cells	NULL
.	NULL

The	NULL
Ba-P210-ICSBP	NULL
cell	NULL
line	NULL
remained	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

BLOOD	NULL
,	NULL
1	NULL
JUNE	NULL
2001	NULL
«	NULL
VOLUME	NULL
97	NULL
,	NULL
NUMBER	NULL
11	NULL
A	NULL
B	NULL
1o	NULL
r	NULL
os	NULL
WHB	NULL
awiy	NULL
|	NULL
BCR	NULL
ABL	NULL
700	NULL
&	NULL
800	NULL
2	NULL
~	NULL
sw	NULL
wae	NULL
pate	NULL
auilih	NULL
|	NULL
c-ACL	NULL
i	NULL
400	NULL
€	NULL
m	NULL
3	NULL
2	NULL
10	NULL
te	NULL
)	NULL
icser	NULL
&	NULL
19	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
Day	NULL
Figure	NULL
1	NULL
.	NULL

ICSBP	NULL
expression	NULL
in	NULL
BCR/ABL	NULL
transformed	NULL
BaF3	NULL
cells	NULL
does	NULL
not	NULL
alter	NULL
their	NULL
growth	NULL
characteristics	NULL
in	NULL
vitro	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Immunoblot	NULL
analysis	NULL
of	NULL
ICSBP	NULL
and	NULL
BCR/ABL	NULL
protein	NULL
expression	NULL
in	NULL
cell	NULL
lines	NULL
.	NULL

Lane	NULL
1	NULL
:	NULL
BaF3	NULL
;	NULL
lane	NULL
2	NULL
:	NULL
Ba-P210	NULL
;	NULL
lane	NULL
3	NULL
:	NULL
Ba-P210-ICSBP	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Growth	NULL
kinetics	NULL
of	NULL
Ba-P210	NULL
and	NULL
Ba-P210-ICSBP	NULL
cells	NULL
.	NULL

J	NULL
,	NULL
Ba-P210	NULL
;	NULL
M	NULL
,	NULL
Ba-P210-ICSBP	NULL
.	NULL

growth	NULL
factor-independent	NULL
and	NULL
resistant	NULL
to	NULL
y-irradiation	NULL
in	NULL
culture	NULL
.	NULL

Two	NULL
independent	NULL
Ba-P210-ICSBP	NULL
cell	NULL
lines	NULL
proliferated	NULL
with	NULL
the	NULL
same	NULL
growth	NULL
kinetics	NULL
as	NULL
their	NULL
parental	NULL
cell	NULL
line	NULL
Ba-P210	NULL
(	NULL
Figure	NULL
1B	NULL
)	NULL
,	NULL
demonstrating	NULL
that	NULL
ICSBP	NULL
expression	NULL
did	NULL
not	NULL
exhibit	NULL
an	NULL
antiproliferative	NULL
effect	NULL
on	NULL
Ba-P210	NULL
cells	NULL
in	NULL
vitro	NULL
.	NULL

Expression	NULL
of	NULL
ICSBP	NULL
antagonized	NULL
BCR/ABL	NULL
induction	NULL
of	NULL
leukemia	NULL
in	NULL
vivo	NULL
When	NULL
injected	NULL
intravenously	NULL
into	NULL
healthy	NULL
syngeneic	NULL
Balb/c	NULL
mice	NULL
,	NULL
Ba-P210	NULL
cells	NULL
induced	NULL
a	NULL
rapidly	NULL
progressive	NULL
leukemia	NULL
that	NULL
killed	NULL
the	NULL
host	NULL
in	NULL
3	NULL
weeks	NULL
(	NULL
Figure	NULL
2A	NULL
)	NULL
.	NULL

Spleens	NULL
from	NULL
injected	NULL
animals	NULL
were	NULL
massively	NULL
enlarged	NULL
(	NULL
10-	NULL
to	NULL
20-fold	NULL
above	NULL
normal	NULL
)	NULL
,	NULL
and	NULL
all	NULL
mice	NULL
had	NULL
a	NULL
pathologic	NULL
burden	NULL
of	NULL
Ba-P210	NULL
cells	NULL
in	NULL
their	NULL
peripheral	NULL
blood	NULL
,	NULL
spleen	NULL
,	NULL
and	NULL
bone	NULL
marrow	NULL
.	NULL

BCR/ABL	NULL
expression	NULL
was	NULL
detected	NULL
by	NULL
RT-PCR	NULL
in	NULL
involved	NULL
tissues	NULL
such	NULL
as	NULL
bone	NULL
marrow	NULL
and	NULL
spleen	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
all	NULL
mice	NULL
receiving	NULL
Ba-P210-ICSBP	NULL
cells	NULL
survived	NULL
(	NULL
maximal	NULL
follow-up	NULL
for	NULL
1	NULL
year	NULL
;	NULL
Figure	NULL
2A	NULL
)	NULL
.	NULL

Peripheral	NULL
blood	NULL
from	NULL
mice	NULL
injected	NULL
with	NULL
Ba-P210-ICSBP	NULL
cells	NULL
was	NULL
monitored	NULL
weekly	NULL
and	NULL
leukemia	NULL
was	NULL
not	NULL
observed	NULL
at	NULL
any	NULL
time	NULL
even	NULL
when	NULL
up	NULL
to	NULL
5	NULL
X	NULL
10	NULL
``	NULL
Ba-P210-ICSBP	NULL
cells	NULL
were	NULL
injected	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
ICSBP	NULL
altered	NULL
the	NULL
leukemic	NULL
behavior	NULL
of	NULL
BCR/ABL	NULL
(	NULL
P210	NULL
)	NULL
-transformed	NULL
BaF3	NULL
cells	NULL
in	NULL
a	NULL
syngeneic	NULL
host	NULL
.	NULL

Intact	NULL
host	NULL
immunity	NULL
was	NULL
necessary	NULL
for	NULL
ICSBP-mediated	NULL
protection	NULL
We	NULL
reasoned	NULL
that	NULL
the	NULL
failure	NULL
of	NULL
Ba-P210-ICSBP	NULL
cells	NULL
to	NULL
induce	NULL
a	NULL
lethal	NULL
leukemia	NULL
in	NULL
Balb/c	NULL
mice	NULL
might	NULL
be	NULL
due	NULL
to	NULL
a	NULL
cell-intrinsic	NULL
proliferation	NULL
defect	NULL
apparent	NULL
only	NULL
in	NULL
vivo	NULL
or	NULL
an	NULL
indirect	NULL
activation	NULL
of	NULL
host	NULL
defense	NULL
mechanisms	NULL
.	NULL

To	NULL
see	NULL
if	NULL
impairment	NULL
of	NULL
host	NULL
defenses	NULL
altered	NULL
tumorigenicity	NULL
in	NULL
vivo	NULL
,	NULL
we	NULL
injected	NULL
10°	NULL
Ba-P210	NULL
or	NULL
A	NULL
Figure	NULL
2	NULL
.	NULL

Ba-P210-ICSBP	NULL
cells	NULL
fail	NULL
to	NULL
induce	NULL
leukemia	NULL
in	NULL
immunocompetent	NULL
mice	NULL
,	NULL
but	NULL
remain	NULL
leukemogenic	NULL
in	NULL
irradiated	NULL
and	NULL
immunodeficient	NULL
mice	NULL
.	NULL

(	NULL
A	NULL
)	NULL
A	NULL
total	NULL
of	NULL
10°	NULL
Ba-P210	NULL
(	NULL
©	NULL
,	NULL
#	NULL
)	NULL
or	NULL
Ba-P210-ICSBP	NULL
cells	NULL
(	NULL
C	NULL
]	NULL
,	NULL
MMI	NULL
)	NULL
was	NULL
injected	NULL
intravenously	NULL
into	NULL
normal	NULL
(	NULL
il	NULL
,	NULL
@	NULL
)	NULL
or	NULL
sublethally	NULL
irradiated	NULL
(	NULL
450	NULL
cGy	NULL
;	NULL
CJ	NULL
,	NULL
©	NULL
)	NULL
Balb/c	NULL
mice	NULL
.	NULL

Ten	NULL
mice	NULL
were	NULL
.	NULL

used	NULL
in	NULL
each	NULL
arm	NULL
.	NULL

(	NULL
B	NULL
)	NULL
NOD/SCID	NULL
mice	NULL
,	NULL
5	NULL
to	NULL
6	NULL
mice	NULL
were	NULL
o	NULL
10	NULL
20	NULL
used	NULL
in	NULL
each	NULL
arm	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Rag-1-deficient	NULL
mice	NULL
;	NULL
5	NULL
mice	NULL
were	NULL
used	NULL
in	NULL
each	NULL
arm	NULL
.	NULL

Survival	NULL
(	NULL
%	NULL
)	NULL
no	NULL
0	NULL
30	NULL
40	NULL
Balb/C	NULL
Days	NULL
after	NULL
injection	NULL
ICSBP-INDUCED	NULL
IMMUNITY	NULL
AGAINST	NULL
BCR/ABL+®	NULL
LEUKEMIA	NULL
_	NULL
3493	NULL
Ba-P210-ICSBP	NULL
cells	NULL
into	NULL
Balb/c	NULL
mice	NULL
exposed	NULL
to	NULL
a	NULL
sublethal	NULL
dose	NULL
of	NULL
irradiation	NULL
(	NULL
450	NULL
cGy	NULL
)	NULL
.	NULL

Both	NULL
mouse	NULL
groups	NULL
developed	NULL
lethal	NULL
leukemia	NULL
and	NULL
died	NULL
with	NULL
comparable	NULL
disease	NULL
latencies	NULL
(	NULL
Figure	NULL
2A	NULL
)	NULL
.	NULL

This	NULL
observation	NULL
demonstrated	NULL
that	NULL
ICSBP	NULL
expression	NULL
in	NULL
Ba-P210	NULL
cells	NULL
did	NULL
not	NULL
alter	NULL
the	NULL
intrinsic	NULL
tumorigenicity	NULL
in	NULL
vivo	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
inability	NULL
of	NULL
Ba-P210-ICSBP	NULL
cells	NULL
to	NULL
induce	NULL
leukemia	NULL
in	NULL
healthy	NULL
Balb/c	NULL
mice	NULL
was	NULL
due	NULL
to	NULL
an	NULL
inhibitory	NULL
mechanism	NULL
that	NULL
could	NULL
be	NULL
destroyed	NULL
by	NULL
y-irradiation	NULL
.	NULL

Because	NULL
a	NULL
major	NULL
effect	NULL
of	NULL
y-irradiation	NULL
is	NULL
compromise	NULL
of	NULL
host	NULL
immunity	NULL
,	NULL
we	NULL
investigated	NULL
the	NULL
importance	NULL
of	NULL
an	NULL
intact	NULL
immune	NULL
system	NULL
using	NULL
immunodeficient	NULL
mice	NULL
.	NULL

We	NULL
injected	NULL
10°	NULL
Ba-P210	NULL
and	NULL
Ba-P210-ICSBP	NULL
cells	NULL
into	NULL
NOD/SCID	NULL
and	NULL
Rag-1	NULL
--	NULL
mice	NULL
.	NULL

NOD/SCID	NULL
mice	NULL
are	NULL
severely	NULL
deficient	NULL
in	NULL
T/B	NULL
cells	NULL
and	NULL
NK	NULL
cells	NULL
,	NULL
``	NULL
and	NULL
Rag-1~~	NULL
mice	NULL
have	NULL
no	NULL
T/B	NULL
cell	NULL
function	NULL
,	NULL
but	NULL
maintain	NULL
relatively	NULL
normal	NULL
function	NULL
of	NULL
NK	NULL
cells	NULL
.	NULL
``	NULL

Similar	NULL
to	NULL
y-irradiated	NULL
Balb/c	NULL
mice	NULL
,	NULL
the	NULL
disease	NULL
latencies	NULL
induced	NULL
by	NULL
both	NULL
Ba-P210	NULL
and	NULL
Ba-P210-ICSBP	NULL
cell	NULL
lines	NULL
were	NULL
comparable	NULL
in	NULL
NOD/SCID	NULL
and	NULL
Rag-1~~-	NULL
mice	NULL
(	NULL
Figure	NULL
2B	NULL
,	NULL
C	NULL
)	NULL
.	NULL

This	NULL
experiment	NULL
strongly	NULL
suggested	NULL
that	NULL
the	NULL
protective	NULL
function	NULL
of	NULL
ICSBP	NULL
was	NULL
dependent	NULL
on	NULL
an	NULL
intact	NULL
immune	NULL
system	NULL
in	NULL
the	NULL
recipient	NULL
mice	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
result	NULL
implicated	NULL
T/B	NULL
cells	NULL
and	NULL
not	NULL
NK	NULL
cells	NULL
in	NULL
the	NULL
process	NULL
.	NULL

Ba-P210-ICSBP	NULL
immunization	NULL
led	NULL
to	NULL
resistance	NULL
against	NULL
subsequent	NULL
rechallenge	NULL
with	NULL
Ba-P210	NULL
cells	NULL
To	NULL
assess	NULL
whether	NULL
the	NULL
induced	NULL
immunity	NULL
was	NULL
directed	NULL
against	NULL
-specific	NULL
antigens	NULL
or	NULL
antigens	NULL
unrelated	NULL
to	NULL
ICSBP	NULL
,	NULL
we	NULL
tested	NULL
whether	NULL
mice	NULL
that	NULL
survived	NULL
Ba-P210-ICSBP	NULL
injection	NULL
could	NULL
survive	NULL
subsequent	NULL
challenge	NULL
with	NULL
parental	NULL
Ba-P210	NULL
cells	NULL
.	NULL

Thirty	NULL
days	NULL
after	NULL
a	NULL
single-dose	NULL
immunization	NULL
with	NULL
Ba-P210-ICSBP	NULL
cells	NULL
,	NULL
mice	NULL
were	NULL
reinjected	NULL
with	NULL
10°	NULL
Ba-P210	NULL
cells	NULL
.	NULL

All	NULL
mice	NULL
tested	NULL
achieved	NULL
long-term	NULL
leukemia-free	NULL
survival	NULL
(	NULL
Figure	NULL
3A	NULL
,	NULL
maximal	NULL
follow-up	NULL
for	NULL
1	NULL
year	NULL
)	NULL
.	NULL

This	NULL
result	NULL
indicated	NULL
that	NULL
tumor	NULL
rejection	NULL
was	NULL
not	NULL
directed	NULL
against	NULL
ICSBP-derived	NULL
antigens	NULL
on	NULL
the	NULL
tumor	NULL
cells	NULL
.	NULL

Immunized	NULL
mice	NULL
rechallenged	NULL
with	NULL
Ba-P210	NULL
cells	NULL
90	NULL
days	NULL
after	NULL
Ba-P210-ICSBP	NULL
immunization	NULL
also	NULL
survived	NULL
,	NULL
demonstrating	NULL
that	NULL
the	NULL
immunity	NULL
induced	NULL
by	NULL
ICSBP	NULL
expression	NULL
in	NULL
Ba-P210	NULL
cells	NULL
was	NULL
potent	NULL
and	NULL
long-lasting	NULL
.	NULL

Mice	NULL
injected	NULL
with	NULL
a	NULL
sublethal	NULL
dose	NULL
of	NULL
Ba-P210	NULL
cells	NULL
(	NULL
<	NULL
5	NULL
X	NULL
10°	NULL
cells	NULL
)	NULL
failed	NULL
to	NULL
develop	NULL
resistance	NULL
to	NULL
subsequent	NULL
challenge	NULL
with	NULL
lethal	NULL
doses	NULL
of	NULL
Ba-P210	NULL
cells	NULL
,	NULL
indicating	NULL
that	NULL
expression	NULL
of	NULL
ICSBP	NULL
was	NULL
critical	NULL
to	NULL
the	NULL
development	NULL
of	NULL
protective	NULL
immunity	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

A	NULL
single	NULL
dose	NULL
of	NULL
y-irradiated	NULL
Ba-P210-ICSBP	NULL
cells	NULL
(	NULL
up	NULL
to	NULL
10	NULL
``	NULL
)	NULL
also	NULL
failed	NULL
to	NULL
induce	NULL
immunity	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Irradiation	NULL
with	NULL
doses	NULL
higher	NULL
than	NULL
2	NULL
Gy	NULL
inhibits	NULL
antigen	NULL
presentation	NULL
by	NULL
B	NULL
cells	NULL
,	NULL
``	NULL
``	NULL
but	NULL
the	NULL
failure	NULL
of	NULL
irradiated	NULL
cells	NULL
to	NULL
induce	NULL
immunity	NULL
also	NULL
suggests	NULL
that	NULL
proliferating	NULL
cells	NULL
expressing	NULL
ICSBP	NULL
are	NULL
required	NULL
to	NULL
stimulate	NULL
a	NULL
protective	NULL
immune	NULL
response	NULL
.	NULL

ICSBP-induced	NULL
immunity	NULL
can	NULL
be	NULL
transferred	NULL
to	NULL
naive	NULL
mice	NULL
The	NULL
spleen	NULL
is	NULL
a	NULL
primary	NULL
immune	NULL
organ	NULL
in	NULL
an	NULL
adult	NULL
mouse	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
immunologic	NULL
memory	NULL
could	NULL
be	NULL
adoptively	NULL
B	NULL
so	NULL
,	NULL
C	NULL
|	NULL
|	NULL
NOD/SCID	NULL
ro	NULL
o	NULL
100	NULL
#	NULL
c	NULL
=	NULL
Survival	NULL
(	NULL
%	NULL
)	NULL
Survival	NULL
(	NULL
%	NULL
)	NULL
ns	NULL
&	NULL
Rag-1	NULL
+	NULL
--	NULL
m-C	NULL
;	NULL
0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
50	NULL
60	NULL
Days	NULL
after	NULL
injection	NULL
50	NULL
60	NULL
0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
50	NULL
60	NULL
Days	NULL
after	NULL
injection	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

3494	NULL
_	NULL
DENG	NULL
and	NULL
DALEY	NULL
A	NULL
B	NULL
120	NULL
120	NULL
531004	NULL
a	NULL
$	NULL
100	NULL
.	NULL

-	NULL
80	NULL
=	NULL
so	NULL
S	NULL
so	NULL
3	NULL
so	NULL
z	NULL
40	NULL
P	NULL
40	NULL
3	NULL
3	NULL
I	NULL
20	NULL
i	NULL
20	NULL
0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
50	NULL
60	NULL
0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
50	NULL
60	NULL
Days	NULL
after	NULL
injection	NULL
Days	NULL
after	NULL
injection	NULL
Figure	NULL
3	NULL
.	NULL

Injection	NULL
of	NULL
ICSBP	NULL
modified	NULL
cells	NULL
(	NULL
Ba-P210-ICSBP	NULL
)	NULL
generates	NULL
immunologic	NULL
memory	NULL
for	NULL
parental	NULL
leukemia	NULL
cells	NULL
(	NULL
Ba-P210	NULL
)	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Survival	NULL
of	NULL
naive	NULL
Balb/c	NULL
mice	NULL
(	NULL
<	NULL
)	NULL
or	NULL
Balb/c	NULL
mice	NULL
preimmunized	NULL
with	NULL
10°	NULL
Ba-P210-ICSBP	NULL
cells	NULL
(	NULL
C	NULL
)	NULL
)	NULL
following	NULL
intravenous	NULL
injection	NULL
with	NULL
10°	NULL
Ba-P210	NULL
cells	NULL
.	NULL

Ten	NULL
mice	NULL
were	NULL
used	NULL
in	NULL
each	NULL
arm	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Balb/c	NULL
mice	NULL
received	NULL
an	NULL
intravenous	NULL
injection	NULL
of	NULL
7	NULL
%	NULL
10°	NULL
spleen	NULL
cells	NULL
from	NULL
naive	NULL
(	NULL
0	NULL
)	NULL
or	NULL
Ba-P210-ICSBP	NULL
immunized	NULL
mice	NULL
(	NULL
C	NULL
)	NULL
)	NULL
,	NULL
along	NULL
with	NULL
10°	NULL
Ba-P210	NULL
cells	NULL
on	NULL
the	NULL
following	NULL
day	NULL
.	NULL

Five	NULL
mice	NULL
were	NULL
used	NULL
in	NULL
each	NULL
arm	NULL
.	NULL

transferred	NULL
from	NULL
one	NULL
animal	NULL
to	NULL
another	NULL
,	NULL
donor	NULL
Balb/c	NULL
mice	NULL
were	NULL
immunized	NULL
with	NULL
a	NULL
single	NULL
dose	NULL
of	NULL
10°	NULL
Ba-P210-ICSBP	NULL
cells	NULL
.	NULL

Four	NULL
weeks	NULL
after	NULL
the	NULL
immunization	NULL
,	NULL
spleens	NULL
were	NULL
removed	NULL
from	NULL
the	NULL
donor	NULL
mice	NULL
,	NULL
single-cell	NULL
suspensions	NULL
were	NULL
made	NULL
,	NULL
and	NULL
6	NULL
X	NULL
10	NULL
``	NULL
mononuclear	NULL
spleen	NULL
cells	NULL
were	NULL
injected	NULL
intravenously	NULL
into	NULL
nonirra-diated	NULL
recipient	NULL
mice	NULL
(	NULL
representing	NULL
about	NULL
half	NULL
the	NULL
total	NULL
cells	NULL
from	NULL
a	NULL
single	NULL
spleen	NULL
)	NULL
.	NULL

At	NULL
the	NULL
time	NULL
of	NULL
spleen	NULL
cell	NULL
transfer	NULL
,	NULL
there	NULL
was	NULL
no	NULL
residual	NULL
Ba-P210-ICSBP	NULL
cells	NULL
detectable	NULL
by	NULL
genomic	NULL
PCR	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Recipient	NULL
mice	NULL
were	NULL
then	NULL
challenged	NULL
with	NULL
10°	NULL
Ba-P210	NULL
cells	NULL
on	NULL
the	NULL
second	NULL
day	NULL
.	NULL

All	NULL
mice	NULL
receiving	NULL
ICSBP-immunized	NULL
spleen	NULL
cells	NULL
were	NULL
protected	NULL
from	NULL
Ba-P210-induced	NULL
leukemia	NULL
,	NULL
whereas	NULL
control	NULL
mice	NULL
receiving	NULL
naive	NULL
spleen	NULL
cells	NULL
died	NULL
of	NULL
leukemia	NULL
with	NULL
the	NULL
expected	NULL
latency	NULL
(	NULL
Figure	NULL
3B	NULL
)	NULL
.	NULL

Ba-P210-ICSBP	NULL
injection	NULL
protected	NULL
mice	NULL
with	NULL
pre-established	NULL
leukemia	NULL
We	NULL
have	NULL
demonstrated	NULL
that	NULL
ectopic	NULL
expression	NULL
of	NULL
ICSBP	NULL
in	NULL
BCR/ABL-transformed	NULL
BaF3	NULL
cells	NULL
induced	NULL
potent	NULL
cellular	NULL
immunity	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
ICSBP-induced	NULL
immunity	NULL
could	NULL
eradicate	NULL
pre-existing	NULL
disease	NULL
,	NULL
we	NULL
first	NULL
injected	NULL
10°	NULL
Ba-P210	NULL
cells	NULL
into	NULL
naive	NULL
Balb/c	NULL
mice	NULL
to	NULL
induce	NULL
leukemia	NULL
.	NULL

A	NULL
single	NULL
dose	NULL
of	NULL
10°	NULL
Ba-P210-ICSBP	NULL
cells	NULL
was	NULL
injected	NULL
simultaneously	NULL
into	NULL
the	NULL
same	NULL
hosts	NULL
,	NULL
or	NULL
following	NULL
a	NULL
delay	NULL
of	NULL
3	NULL
,	NULL
7	NULL
,	NULL
or	NULL
14	NULL
days	NULL
.	NULL

Simultaneous	NULL
injection	NULL
of	NULL
both	NULL
cell	NULL
lines	NULL
allowed	NULL
survival	NULL
of	NULL
all	NULL
mice	NULL
(	NULL
Figure	NULL
4	NULL
)	NULL
.	NULL

More	NULL
strikingly	NULL
,	NULL
all	NULL
mice	NULL
survived	NULL
even	NULL
when	NULL
Ba-P210-ICSBP	NULL
cells	NULL
were	NULL
injected	NULL
3	NULL
or	NULL
7	NULL
days	NULL
after	NULL
the	NULL
injection	NULL
of	NULL
the	NULL
leukemic	NULL
Ba-P210	NULL
cells	NULL
.	NULL

When	NULL
leukemia	NULL
was	NULL
allowed	NULL
to	NULL
develop	NULL
for	NULL
14	NULL
days	NULL
,	NULL
equivalent	NULL
to	NULL
two	NULL
thirds	NULL
of	NULL
the	NULL
disease	NULL
latency	NULL
,	NULL
all	NULL
mice	NULL
achieved	NULL
prolonged	NULL
survival	NULL
and	NULL
20	NULL
%	NULL
of	NULL
the	NULL
mice	NULL
survived	NULL
disease	NULL
free	NULL
.	NULL

The	NULL
results	NULL
demonstrated	NULL
that	NULL
the	NULL
antileukemic	NULL
effect	NULL
of	NULL
the	NULL
immunized	NULL
cells	NULL
could	NULL
be	NULL
initiated	NULL
rapidly	NULL
and	NULL
that	NULL
ectopic	NULL
ICSBP	NULL
expression	NULL
in	NULL
leukemic	NULL
cells	NULL
was	NULL
potent	NULL
enough	NULL
to	NULL
eradicate	NULL
established	NULL
disease	NULL
.	NULL

CTLs	NULL
were	NULL
induced	NULL
by	NULL
Ba-P210-ICSBP	NULL
immunization	NULL
To	NULL
determine	NULL
whether	NULL
mice	NULL
immunized	NULL
with	NULL
Ba-P210-ICSBP	NULL
cells	NULL
generated	NULL
CTLs	NULL
against	NULL
BCR/ABL	NULL
transformed	NULL
BaF3	NULL
cells	NULL
,	NULL
spleens	NULL
from	NULL
naive	NULL
or	NULL
immunized	NULL
Balb/c	NULL
mice	NULL
were	NULL
isolated	NULL
2	NULL
weeks	NULL
after	NULL
immunization	NULL
and	NULL
tested	NULL
in	NULL
a	NULL
cytotoxicity	NULL
assay	NULL
.	NULL

Single-cell	NULL
suspensions	NULL
were	NULL
cultured	NULL
for	NULL
6	NULL
days	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
y-irradiated	NULL
Ba-P210-ICSBP	NULL
cells	NULL
to	NULL
stimulate	NULL
specific	NULL
CTL	NULL
proliferation	NULL
in	NULL
vitro	NULL
.	NULL

A	NULL
5'Cr-release	NULL
assay	NULL
was	NULL
performed	NULL
on	NULL
day	NULL
7	NULL
.	NULL

Spleen	NULL
cells	NULL
from	NULL
immunized	NULL
mice	NULL
lysed	NULL
both	NULL
Ba-P210	NULL
and	NULL
Ba-P210-ICSBP	NULL
cells	NULL
at	NULL
comparable	NULL
levels	NULL
(	NULL
maximum	NULL
of	NULL
94.1	NULL
%	NULL
and	NULL
84.9	NULL
%	NULL
,	NULL
respectively	NULL
;	NULL
Figure	NULL
5A	NULL
)	NULL
.	NULL

No	NULL
cytolytic	NULL
activity	NULL
was	NULL
observed	NULL
when	NULL
naive	NULL
spleen	NULL
cells	NULL
were	NULL
used	NULL
as	NULL
effector	NULL
cells	NULL
,	NULL
or	NULL
when	NULL
M-MSV-transformed	NULL
3T3	NULL
(	NULL
Balb/c	NULL
derived	NULL
)	NULL
or	NULL
LL2	NULL
Lewis	NULL
lung	NULL
carcinoma	NULL
BLOOD	NULL
,	NULL
1	NULL
JUNE	NULL
2001	NULL
»	NULL
VOLUME	NULL
97	NULL
,	NULL
NUMBER	NULL
11	NULL
(	NULL
C57BL/6	NULL
derived	NULL
)	NULL
cells	NULL
were	NULL
used	NULL
as	NULL
targets	NULL
.	NULL

This	NULL
result	NULL
not	NULL
only	NULL
demonstrated	NULL
the	NULL
generation	NULL
of	NULL
specific	NULL
CTLs	NULL
from	NULL
in	NULL
vivo	NULL
immunization	NULL
,	NULL
but	NULL
also	NULL
confirmed	NULL
that	NULL
ICSBP-derived	NULL
antigens	NULL
were	NULL
unlikely	NULL
to	NULL
be	NULL
the	NULL
targets	NULL
recognized	NULL
by	NULL
CTLs	NULL
.	NULL

Cytotoxicity	NULL
was	NULL
also	NULL
observed	NULL
when	NULL
BaF3	NULL
cells	NULL
were	NULL
used	NULL
as	NULL
targets	NULL
,	NULL
though	NULL
at	NULL
a	NULL
lower	NULL
level	NULL
,	NULL
indicating	NULL
that	NULL
antigens	NULL
on	NULL
BaF3	NULL
cells	NULL
were	NULL
also	NULL
targets	NULL
of	NULL
the	NULL
immune	NULL
response	NULL
initiated	NULL
by	NULL
ICSBP	NULL
expression	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
investigate	NULL
whether	NULL
there	NULL
were	NULL
specific	NULL
CTLs	NULL
directed	NULL
against	NULL
BCR/ABL-associated	NULL
antigens	NULL
,	NULL
we	NULL
performed	NULL
competition	NULL
assays	NULL
with	NULL
unlabeled	NULL
target	NULL
cells	NULL
.	NULL

Either	NULL
BaF3	NULL
or	NULL
Ba-P210	NULL
cells	NULL
were	NULL
added	NULL
in	NULL
excess	NULL
as	NULL
unlabeled	NULL
cells	NULL
to	NULL
compete	NULL
against	NULL
*Cr-labeled	NULL
target	NULL
Ba-P210	NULL
cells	NULL
in	NULL
cytotoxicity	NULL
assays	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
excess	NULL
unlabeled	NULL
Ba-P210	NULL
cells	NULL
was	NULL
significantly	NULL
more	NULL
effective	NULL
at	NULL
inhibition	NULL
of	NULL
ICSBP-induced	NULL
spleen	NULL
cell	NULL
cytotoxicity	NULL
than	NULL
a	NULL
comparable	NULL
number	NULL
of	NULL
unlabeled	NULL
BaF3	NULL
cells	NULL
(	NULL
Figure	NULL
5B	NULL
)	NULL
.	NULL

This	NULL
result	NULL
confirmed	NULL
that	NULL
a	NULL
proportion	NULL
of	NULL
spleen	NULL
CTLs	NULL
were	NULL
directed	NULL
against	NULL
antigens	NULL
associated	NULL
with	NULL
BCR/ABL	NULL
expression	NULL
,	NULL
whereas	NULL
other	NULL
CTLs	NULL
recognized	NULL
antigens	NULL
associated	NULL
with	NULL
the	NULL
BaF3	NULL
cells	NULL
.	NULL

CD8+*	NULL
cells	NULL
were	NULL
the	NULL
primary	NULL
effector	NULL
cells	NULL
mediating	NULL
ICSBP-induced	NULL
immunity	NULL
To	NULL
characterize	NULL
which	NULL
T-cell	NULL
subtype	NULL
mediated	NULL
the	NULL
cytotoxic	NULL
effect	NULL
we	NULL
observed	NULL
,	NULL
we	NULL
isolated	NULL
CD8+*	NULL
or	NULL
CD4	NULL
*	NULL
cells	NULL
from	NULL
the	NULL
immunized	NULL
total	NULL
spleen	NULL
cell	NULL
population	NULL
by	NULL
immunoaffinity	NULL
fractionation	NULL
.	NULL

Both	NULL
positively	NULL
selected	NULL
CD8+*	NULL
or	NULL
CD4*	NULL
cells	NULL
and	NULL
the	NULL
corresponding	NULL
depleted	NULL
cell	NULL
populations	NULL
were	NULL
used	NULL
for	NULL
CTL	NULL
assays	NULL
.	NULL

As	NULL
determined	NULL
by	NULL
flow	NULL
cytometry	NULL
,	NULL
positively	NULL
selected	NULL
cells	NULL
were	NULL
more	NULL
than	NULL
85	NULL
%	NULL
pure	NULL
and	NULL
depletions	NULL
for	NULL
both	NULL
CD4*	NULL
and	NULL
CD8*	NULL
cells	NULL
were	NULL
more	NULL
than	NULL
97	NULL
%	NULL
efficient	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Consistently	NULL
,	NULL
purified	NULL
CD8*	NULL
cells	NULL
exhibited	NULL
about	NULL
80	NULL
%	NULL
CTL	NULL
activity	NULL
,	NULL
whereas	NULL
CD8*	NULL
depletion	NULL
resulted	NULL
in	NULL
more	NULL
than	NULL
85	NULL
%	NULL
loss	NULL
of	NULL
CTL	NULL
activity	NULL
(	NULL
Figure	NULL
5C	NULL
)	NULL
.	NULL

CD4+*	NULL
depletion	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
CTL	NULL
activity	NULL
,	NULL
whereas	NULL
purified	NULL
CD4+*	NULL
cells	NULL
elicited	NULL
only	NULL
20	NULL
%	NULL
activity	NULL
.	NULL

These	NULL
results	NULL
suggested	NULL
that	NULL
CD8+	NULL
cells	NULL
were	NULL
the	NULL
primary	NULL
cytotoxic	NULL
effector	NULL
cells	NULL
in	NULL
vitro	NULL
and	NULL
therefore	NULL
likely	NULL
to	NULL
account	NULL
for	NULL
ICSBP-induced	NULL
cellular	NULL
immunity	NULL
in	NULL
vivo	NULL
.	NULL

Discussion	NULL
Previous	NULL
studies	NULL
linked	NULL
ICSBP	NULL
deficiency	NULL
to	NULL
the	NULL
pathogenesis	NULL
of	NULL
myeloproliferative	NULL
disease	NULL
in	NULL
mice	NULL
and	NULL
humans	NULL
and	NULL
correlated	NULL
restoration	NULL
of	NULL
ICSBP	NULL
expression	NULL
with	NULL
the	NULL
action	NULL
of	NULL
IFN	NULL
against	NULL
120	NULL
0-,3-	NULL
,	NULL
7-day	NULL
delay	NULL
§	NULL
100	NULL
?	NULL

-	NULL
-	NULL
80	NULL
S	NULL
60	NULL
|	NULL
ja	NULL
49	NULL
Naive	NULL
3	NULL
14-day	NULL
delay	NULL
w	NULL
-	NULL
20	NULL
___	NULL
2	NULL
,	NULL
0	NULL
_	NULL
10	NULL
20	NULL
30	NULL
40	NULL
50	NULL
60	NULL
Days	NULL
after	NULL
injection	NULL
Figure	NULL
4	NULL
.	NULL

Ba-P210-ICSBP	NULL
immunization	NULL
rescues	NULL
mice	NULL
with	NULL
pre-established	NULL
leukemia	NULL
.	NULL

Survival	NULL
of	NULL
Balb/c	NULL
mice	NULL
injected	NULL
with	NULL
10°	NULL
Ba-P210	NULL
cells	NULL
,	NULL
followed	NULL
by	NULL
10°	NULL
Ba-P210-ICSBP	NULL
cells	NULL
injected	NULL
on	NULL
the	NULL
same	NULL
day	NULL
or	NULL
after	NULL
a	NULL
delay	NULL
of	NULL
3	NULL
,	NULL
7	NULL
,	NULL
or	NULL
14	NULL
days	NULL
.	NULL

Control	NULL
mice	NULL
(	NULL
naive	NULL
)	NULL
received	NULL
no	NULL
Ba-P210-ICSBP	NULL
cells	NULL
.	NULL

Five	NULL
mice	NULL
were	NULL
used	NULL
in	NULL
each	NULL
arm	NULL
.	NULL

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

BLOOD	NULL
,	NULL
1	NULL
JUNE	NULL
2001	NULL
«	NULL
VOLUME	NULL
97	NULL
,	NULL
NUMBER	NULL
11	NULL
10	NULL
&	NULL
90	NULL
70	NULL
&	NULL
so	NULL
5	NULL
60	NULL
a	NULL
70	NULL
'S	NULL
50	NULL
2	NULL
,	NULL
so	NULL
2	NULL
ao	NULL
``	NULL
J	NULL
so	NULL
4	NULL
2	NULL
40	NULL
-A	NULL
30	NULL
b=l	NULL
E=	NULL
C	NULL
$	NULL
n	NULL
o	NULL
ts	NULL
®	NULL
10	NULL
10	NULL
0	NULL
0	NULL
EMT	NULL
0	NULL
5	NULL
25	NULL
50	NULL
100	NULL
No	NULL
competitor	NULL
ICSBP-INDUCED	NULL
IMMUNITY	NULL
AGAINST	NULL
BCR/ABL+®	NULL
LEUKEMIA	NULL
_	NULL
3495	NULL
120	NULL
2	NULL
£100	NULL
7L	NULL
?	NULL

BaP20	NULL
T	NULL
,	NULL
)	NULL
)	NULL
|	NULL
._	NULL
bz	NULL
i	NULL
]	NULL
b	NULL
:	NULL
3	NULL
91	NULL
}	NULL
.	NULL

5	NULL
f	NULL
BaF3	NULL
42049	NULL
]	NULL
|	NULL
5	NULL
9	NULL
20	NULL
t	NULL
]	NULL
Ces	NULL
E	NULL
=	NULL
ol	NULL
lL-L	NULL
--	NULL
t	NULL
=	NULL
40x	NULL
90x	NULL
Total	NULL
CD8+	NULL
CD4	NULL
CD8	NULL
CD4	NULL
spleen	NULL
cells	NULL
depleted	NULL
depleted	NULL
Figure	NULL
5	NULL
.	NULL

Immunization	NULL
with	NULL
Ba-P210-ICSBP	NULL
cells	NULL
activates	NULL
CD8+	NULL
CTLs	NULL
,	NULL
which	NULL
exhibit	NULL
specific	NULL
cytolytic	NULL
activity	NULL
against	NULL
BCR/ABL-associated	NULL
cell	NULL
surface	NULL
antigens	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Cytolytic	NULL
activity	NULL
of	NULL
Ba-P210-ICSBP	NULL
immunized	NULL
spleen	NULL
cells	NULL
against	NULL
different	NULL
cell	NULL
targets	NULL
.	NULL

Five	NULL
thousand	NULL
5'Cr-labeled	NULL
target	NULL
cells	NULL
were	NULL
used	NULL
:	NULL
©	NULL
,	NULL
Ba-P210	NULL
;	NULL
C	NULL
,	NULL
Ba-P210-ICSBP	NULL
;	NULL
®	NULL
,	NULL
3T3-MSV	NULL
;	NULL
M	NULL
,	NULL
LL2	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Cytotoxicity	NULL
competition	NULL
assay	NULL
;	NULL
5000	NULL
Cr	NULL
labeled	NULL
Ba-P210	NULL
cells	NULL
were	NULL
used	NULL
as	NULL
target	NULL
cells	NULL
,	NULL
and	NULL
125	NULL
000	NULL
Ba-P210-ICSBP	NULL
immunized	NULL
spleen	NULL
cells	NULL
were	NULL
used	NULL
as	NULL
effector-cells	NULL
(	NULL
effector-target	NULL
ratio	NULL
of	NULL
25:1	NULL
)	NULL
.	NULL

An	NULL
excess	NULL
of	NULL
unlabeled	NULL
BaF3	NULL
or	NULL
Ba-P210	NULL
cells	NULL
were	NULL
added	NULL
to	NULL
the	NULL
target-effector	NULL
mixture	NULL
(	NULL
40-fold	NULL
or	NULL
90-fold	NULL
as	NULL
indicated	NULL
)	NULL
.	NULL

CTL	NULL
activity	NULL
was	NULL
measured	NULL
as	NULL
described	NULL
in	NULL
``	NULL
Materials	NULL
and	NULL
methods	NULL
.	NULL
``	NULL

Graph	NULL
represents	NULL
the	NULL
percentage	NULL
of	NULL
inhibition	NULL
of	NULL
cytolytic	NULL
activity	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
unlabeled	NULL
cells	NULL
normalized	NULL
against	NULL
total	NULL
cytolytic	NULL
activity	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
unlabeled	NULL
cells	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Cytolytic	NULL
activities	NULL
of	NULL
CD8*/CD4*	NULL
cells	NULL
or	NULL
the	NULL
corresponding	NULL
CD8/CD4-depleted	NULL
Ba-P210-ICSBP	NULL
immunized	NULL
spleen	NULL
cells	NULL
.	NULL

Five	NULL
thousand	NULL
Ba-P210	NULL
cells	NULL
were	NULL
used	NULL
as	NULL
target	NULL
and	NULL
the	NULL
effector-target	NULL
cell	NULL
ratio	NULL
was	NULL
25:1	NULL
.	NULL

CML	NULL
.	NULL
``	NULL

In	NULL
the	NULL
present	NULL
study	NULL
we	NULL
have	NULL
made	NULL
the	NULL
surprising	NULL
observation	NULL
that	NULL
ectopic	NULL
expression	NULL
of	NULL
ICSBP	NULL
,	NULL
an	NULL
IFN-regulated	NULL
transcription	NULL
factor	NULL
,	NULL
induces	NULL
a	NULL
rapid	NULL
,	NULL
potent	NULL
,	NULL
and	NULL
long-lasting	NULL
vaccine-like	NULL
effect	NULL
against	NULL
BCR/ABL-transformed	NULL
BaF3	NULL
cells	NULL
in	NULL
a	NULL
murine	NULL
leukemia	NULL
model	NULL
.	NULL

A	NULL
single-dose	NULL
injection	NULL
with	NULL
ICSBP-modified	NULL
cells	NULL
can	NULL
eradicate	NULL
pre-established	NULL
leukemia	NULL
in	NULL
this	NULL
model	NULL
,	NULL
and	NULL
in	NULL
vitro	NULL
cellular	NULL
cytotoxicity	NULL
assays	NULL
implicate	NULL
CD8+*	NULL
T	NULL
cell	NULL
immunoreactivity	NULL
against	NULL
leukemic	NULL
targets	NULL
.	NULL

As	NULL
a	NULL
modulator	NULL
of	NULL
IFN	NULL
signaling	NULL
,	NULL
ICSBP	NULL
might	NULL
activate	NULL
or	NULL
repress	NULL
genes	NULL
that	NULL
contribute	NULL
to	NULL
the	NULL
therapeutic	NULL
effect	NULL
of	NULL
IFN-	NULL
«	NULL
by	NULL
enhancing	NULL
immune	NULL
recognition	NULL
of	NULL
malignant	NULL
cells	NULL
.	NULL

Unraveling	NULL
the	NULL
mechanism	NULL
by	NULL
which	NULL
ICSBP	NULL
expression	NULL
stimulates	NULL
protective	NULL
immune	NULL
surveillance	NULL
against	NULL
BCR/	NULL
ABL-transformed	NULL
BaF3	NULL
cells	NULL
may	NULL
lead	NULL
to	NULL
novel	NULL
approaches	NULL
to	NULL
leukemia	NULL
immunotherapy	NULL
.	NULL

Allogeneic	NULL
BMT	NULL
and	NULL
donor	NULL
lymphocyte	NULL
infusion	NULL
induce	NULL
a	NULL
potent	NULL
graft-versus-leukemia	NULL
effect	NULL
,	NULL
a	NULL
form	NULL
of	NULL
immunotherapy	NULL
that	NULL
has	NULL
a	NULL
major	NULL
therapeutic	NULL
benefit	NULL
in	NULL
CML	NULL
.	NULL
``	NULL

Philadelphia	NULL
chromosome	NULL
,	NULL
positive	NULL
cells	NULL
persist	NULL
in	NULL
bone	NULL
marrow	NULL
and	NULL
blood	NULL
samples	NULL
of	NULL
patients	NULL
with	NULL
CML	NULL
who	NULL
are	NULL
in	NULL
clinical	NULL
remission	NULL
after	NULL
transplant	NULL
or	NULL
chronic	NULL
IFN	NULL
therapy	NULL
,	NULL
supporting	NULL
the	NULL
notion	NULL
that	NULL
active	NULL
mechanisms	NULL
of	NULL
immunosuppression	NULL
play	NULL
a	NULL
role	NULL
in	NULL
maintaining	NULL
leukemia	NULL
in	NULL
a	NULL
dormant	NULL
state	NULL
.	NULL
``	NULL

''	NULL
Given	NULL
that	NULL
BCR/ABL	NULL
represents	NULL
a	NULL
novel	NULL
tumor-specific	NULL
antigen	NULL
,	NULL
BCR/ABL	NULL
peptides	NULL
have	NULL
been	NULL
intensively	NULL
studied	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
trigger	NULL
specific	NULL
immunity	NULL
.	NULL

Indeed	NULL
,	NULL
peptides	NULL
from	NULL
the	NULL
fusion	NULL
sequences	NULL
of	NULL
BCR/ABL	NULL
are	NULL
bound	NULL
by	NULL
HLA	NULL
molecules	NULL
,	NULL
and	NULL
BCR/ABL	NULL
peptide-sensitized	NULL
dendritic	NULL
cells	NULL
can	NULL
generate	NULL
cellular	NULL
immune	NULL
reactivity	NULL
.	NULL

``	NULL
*°	NULL
Hints	NULL
of	NULL
specific	NULL
immunity	NULL
against	NULL
CML	NULL
cells	NULL
have	NULL
been	NULL
gleaned	NULL
from	NULL
clinical	NULL
trials	NULL
in	NULL
which	NULL
patients	NULL
have	NULL
been	NULL
immunized	NULL
with	NULL
BCR/ABL	NULL
fusion	NULL
In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
demonstrated	NULL
that	NULL
cytotoxic	NULL
T	NULL
cells	NULL
generated	NULL
by	NULL
Ba-P210-ICSBP	NULL
immunization	NULL
were	NULL
directed	NULL
against	NULL
antigens	NULL
associated	NULL
with	NULL
BCR/ABL	NULL
expression	NULL
on	NULL
leukemia	NULL
cells	NULL
.	NULL

It	NULL
is	NULL
therefore	NULL
tempting	NULL
to	NULL
speculate	NULL
that	NULL
ICSBP	NULL
enhances	NULL
the	NULL
presentation	NULL
of	NULL
BCR/ABL-derived	NULL
peptides	NULL
,	NULL
but	NULL
confirmation	NULL
of	NULL
this	NULL
requires	NULL
the	NULL
isolation	NULL
of	NULL
specific	NULL
CTL	NULL
clones	NULL
and	NULL
definition	NULL
of	NULL
the	NULL
target	NULL
epitopes	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
antigens	NULL
whose	NULL
expression	NULL
is	NULL
induced	NULL
by	NULL
BCR/ABL	NULL
may	NULL
also	NULL
contribute	NULL
to	NULL
active	NULL
immune	NULL
suppression	NULL
.	NULL

A	NULL
recent	NULL
report	NULL
documented	NULL
that	NULL
some	NULL
patients	NULL
with	NULL
CML	NULL
in	NULL
remission	NULL
harbor	NULL
antigen-specific	NULL
T	NULL
cells	NULL
targeted	NULL
against	NULL
epitopes	NULL
of	NULL
the	NULL
proteinase-3	NULL
component	NULL
of	NULL
neutrophil	NULL
granules	NULL
.	NULL
``	NULL

The	NULL
molecular	NULL
basis	NULL
for	NULL
the	NULL
immunostimulatory	NULL
effect	NULL
of	NULL
ICSBP	NULL
expression	NULL
in	NULL
BCR/ABL-transformed	NULL
BaF3	NULL
cells	NULL
is	NULL
unclear	NULL
,	NULL
but	NULL
we	NULL
have	NULL
considered	NULL
2	NULL
possible	NULL
mechanisms	NULL
.	NULL

First	NULL
,	NULL
ICSBP	NULL
may	NULL
enhance	NULL
antigen	NULL
presentation	NULL
or	NULL
immune	NULL
effector	NULL
cell	NULL
recognition	NULL
by	NULL
modulating	NULL
expression	NULL
of	NULL
MHC	NULL
or	NULL
costimulatory	NULL
molecules	NULL
.	NULL

ICSBP	NULL
can	NULL
negatively	NULL
regulate	NULL
MHC	NULL
class	NULL
I	NULL
gene	NULL
which	NULL
might	NULL
render	NULL
cells	NULL
susceptible	NULL
to	NULL
clearance	NULL
by	NULL
NK	NULL
cells	NULL
.	NULL

We	NULL
examined	NULL
both	NULL
MHC	NULL
class	NULL
I	NULL
(	NULL
H-2D	NULL
%	NULL
and	NULL
H-2K	NULL
``	NULL
)	NULL
and	NULL
class	NULL
II	NULL
(	NULL
I-A4	NULL
and	NULL
I-E	NULL
'	NULL
)	NULL
expression	NULL
in	NULL
our	NULL
cell	NULL
lines	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

BaF3	NULL
cells	NULL
expressed	NULL
relatively	NULL
high	NULL
levels	NULL
of	NULL
cell	NULL
surface	NULL
MHC	NULL
class	NULL
I	NULL
,	NULL
which	NULL
was	NULL
increased	NULL
modestly	NULL
on	NULL
transformation	NULL
by	NULL
BCR/ABL	NULL
.	NULL

ICSBP	NULL
overexpression	NULL
did	NULL
not	NULL
alter	NULL
the	NULL
cell	NULL
surface-expression	NULL
of	NULL
MHC	NULL
class	NULL
I.	NULL
MHC	NULL
class	NULL
II	NULL
expression	NULL
was	NULL
not	NULL
detected	NULL
in	NULL
any	NULL
of	NULL
our	NULL
BaF3	NULL
cell	NULL
lines	NULL
.	NULL

Because	NULL
costimulatory	NULL
proteins	NULL
facilitate	NULL
the	NULL
interaction	NULL
between	NULL
antigen-presenting	NULL
cells	NULL
and	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
the	NULL
costimulatory	NULL
molecule	NULL
B7	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
induce	NULL
cellular	NULL
immunity	NULL
against	NULL
BCR/ABL-induced	NULL
leukemia	NULL
,	NULL
``	NULL
we	NULL
examined	NULL
B7	NULL
expression	NULL
in	NULL
our	NULL
ICSBP-modified	NULL
cells	NULL
.	NULL

BaF3	NULL
cells	NULL
express	NULL
low	NULL
levels	NULL
of	NULL
B7-1	NULL
and	NULL
undetectable	NULL
levels	NULL
of	NULL
B7-2	NULL
,	NULL
neither	NULL
of	NULL
which	NULL
were	NULL
altered	NULL
by	NULL
expression	NULL
of	NULL
ICSBP	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
could	NULL
not	NULL
find	NULL
evidence	NULL
that	NULL
the	NULL
ICSBP-induced	NULL
immune	NULL
response	NULL
against	NULL
BCR/	NULL
ABL-transformed	NULL
BaF3	NULL
cells	NULL
was	NULL
due	NULL
to	NULL
altered	NULL
MHC	NULL
or	NULL
B7	NULL
function	NULL
.	NULL

Second	NULL
,	NULL
we	NULL
investigated	NULL
whether	NULL
ICSBP	NULL
induced	NULL
the	NULL
secretion	NULL
of	NULL
cytokines	NULL
that	NULL
stimulate	NULL
dendritic	NULL
or	NULL
T-cell	NULL
function	NULL
.	NULL

ICSBP-deficient	NULL
mice	NULL
are	NULL
markedly	NULL
impaired	NULL
in	NULL
their	NULL
production	NULL
of	NULL
the	NULL
T-helper	NULL
type	NULL
1	NULL
cytokines	NULL
IL-12	NULL
and	NULL
IFN-y	NULL
and	NULL
have	NULL
compromised	NULL
Th-1-driven	NULL
immunity	NULL
.	NULL

``	NULL
*	NULL
``	NULL
``	NULL
Both	NULL
IL-12	NULL
and	NULL
IFN-y	NULL
are	NULL
among	NULL
the	NULL
most	NULL
potent	NULL
antitumor	NULL
cytokines	NULL
.	NULL

IL-12-modified	NULL
tumor	NULL
cells	NULL
activate	NULL
CD8*	NULL
cytotoxic	NULL
T	NULL
cells	NULL
and	NULL
tumor	NULL
rejection	NULL
in	NULL
animal	NULL
models	NULL
,	NULL
``	NULL
whereas	NULL
IFN-y	NULL
possesses	NULL
both	NULL
direct	NULL
antiproliferative	NULL
activity	NULL
and	NULL
immunomodulating	NULL
properties	NULL
,	NULL
including	NULL
activation	NULL
of	NULL
macrophages	NULL
and	NULL
enhancement	NULL
of	NULL
T-cell-mediated	NULL
immunity	NULL
.	NULL
``	NULL

Recently	NULL
,	NULL
it	NULL
was	NULL
shown	NULL
that	NULL
overexpression	NULL
of	NULL
ICSBP	NULL
stimulates	NULL
IL-12	NULL
p40	NULL
promoter	NULL
activity	NULL
in	NULL
macrophages	NULL
.	NULL
``	NULL

We	NULL
tested	NULL
whether	NULL
enhanced	NULL
secretion	NULL
of	NULL
IL-12	NULL
or	NULL
IFN-y	NULL
or	NULL
both	NULL
could	NULL
be	NULL
responsible	NULL
for	NULL
the	NULL
immunoprotective	NULL
activity	NULL
of	NULL
ICSBP-expressing	NULL
cells	NULL
in	NULL
vivo	NULL
.	NULL

We	NULL
measured	NULL
the	NULL
levels	NULL
of	NULL
IL-12	NULL
,	NULL
IFN-y	NULL
,	NULL
and	NULL
GM-CSF	NULL
,	NULL
another	NULL
potent	NULL
antitumor	NULL
cytokine	NULL
,	NULL
``	NULL
``	NULL
in	NULL
conditioned	NULL
culture	NULL
medium	NULL
of	NULL
ICBSP-modified	NULL
BaF3	NULL
cells	NULL
.	NULL

None	NULL
of	NULL
these	NULL
cytokines	NULL
was	NULL
detected	NULL
by	NULL
ELISA	NULL
from	NULL
Ba-P210	NULL
or	NULL
Ba-P210-ICSBP	NULL
cells	NULL
.	NULL

Moreover	NULL
,	NULL
we	NULL
failed	NULL
to	NULL
detect	NULL
altered	NULL
mRNA	NULL
expression	NULL
for	NULL
these	NULL
cytokines	NULL
by	NULL
microarray	NULL
expression	NULL
profiling	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
mechanism	NULL
by	NULL
which	NULL
ICSBP	NULL
induces	NULL
antileukemia	NULL
immunity	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
be	NULL
a	NULL
direct	NULL
consequence	NULL
of	NULL
increased	NULL
secretion	NULL
of	NULL
these	NULL
cytokines	NULL
by	NULL
ICSBP-modified	NULL
cells	NULL
.	NULL

The	NULL
vaccine-like	NULL
effect	NULL
in	NULL
our	NULL
system	NULL
appeared	NULL
to	NULL
require	NULL
coexpression	NULL
of	NULL
ICSBP	NULL
and	NULL
BCR/ABL	NULL
in	NULL
BaF3	NULL
cells	NULL
.	NULL

We	NULL
attempted	NULL
to	NULL
determine	NULL
whether	NULL
ICSBP	NULL
expression	NULL
would	NULL
stimulate	NULL
immune	NULL
rejection	NULL
of	NULL
cytokine-independent	NULL
leukemogenic	NULL
subclones	NULL
of	NULL
BaF3	NULL
that	NULL
arise	NULL
spontaneously	NULL
after	NULL
prolonged	NULL
liquid	NULL
culture	NULL
.	NULL

The	NULL
ICSBP-expressing	NULL
,	NULL
spontaneously	NULL
transformed	NULL
BaF3	NULL
cells	NULL
were	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

3496	NULL
_	NULL
DENG	NULL
and	NULL
DALEY	NULL
incapable	NULL
of	NULL
triggering	NULL
an	NULL
effective	NULL
immune	NULL
response	NULL
on	NULL
their	NULL
own	NULL
.	NULL

However	NULL
,	NULL
once	NULL
the	NULL
immune	NULL
response	NULL
was	NULL
established	NULL
by	NULL
Ba-P210-ICSBP	NULL
injection	NULL
,	NULL
mice	NULL
were	NULL
resistant	NULL
to	NULL
challenges	NULL
from	NULL
both	NULL
Ba-P210	NULL
or	NULL
spontaneously	NULL
transformed	NULL
BaF3	NULL
clones	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
result	NULL
was	NULL
consistent	NULL
with	NULL
our	NULL
CTL	NULL
assays	NULL
that	NULL
showed	NULL
that	NULL
CTLs	NULL
derived	NULL
from	NULL
Ba-P210-ICSBP-immunized	NULL
mice	NULL
also	NULL
lysed	NULL
BaF3	NULL
target	NULL
cells	NULL
.	NULL

Presentation	NULL
of	NULL
BCR/ABL-associated	NULL
epitopes	NULL
may	NULL
be	NULL
particularly	NULL
effective	NULL
in	NULL
ICSBP-expressing	NULL
BaF3	NULL
cells	NULL
,	NULL
which	NULL
are	NULL
derived	NULL
from	NULL
the	NULL
Balb/c	NULL
strain	NULL
,	NULL
because	NULL
we	NULL
have	NULL
been	NULL
unable	NULL
to	NULL
demonstrate	NULL
that	NULL
ICSBP	NULL
expression	NULL
stimulates	NULL
the	NULL
same	NULL
protective	NULL
immunity	NULL
against	NULL
BCR/ABL-transformed	NULL
32D	NULL
cells	NULL
in	NULL
syngeneic	NULL
C3H/HeJ	NULL
mice	NULL
.	NULL

Future	NULL
efforts	NULL
will	NULL
be	NULL
aimed	NULL
at	NULL
determining	NULL
specific	NULL
peptide	NULL
epitopes	NULL
from	NULL
BCR/ABL	NULL
that	NULL
can	NULL
bind	NULL
to	NULL
and	NULL
be	NULL
effectively	NULL
presented	NULL
in	NULL
the	NULL
context	NULL
of	NULL
the	NULL
Balb/c	NULL
class	NULL
I	NULL
molecules	NULL
(	NULL
H-2D4	NULL
,	NULL
H-2K©	NULL
)	NULL
.	NULL

Ren	NULL
and	NULL
colleagues	NULL
have	NULL
demonstrated	NULL
that	NULL
enforced	NULL
coexpression	NULL
of	NULL
ICSBP	NULL
attenuates	NULL
and	NULL
alters	NULL
the	NULL
disease	NULL
phenotype	NULL
induced	NULL
by	NULL
BCR/ABL	NULL
in	NULL
a	NULL
murine	NULL
model	NULL
of	NULL
CML	NULL
,	NULL
*	NULL
``	NULL
but	NULL
the	NULL
precise	NULL
mechanism	NULL
for	NULL
this	NULL
effect	NULL
or	NULL
whether	NULL
an	NULL
immune	NULL
phenomenon	NULL
BLOOD	NULL
,	NULL
1	NULL
JUNE	NULL
2001	NULL
»	NULL
VOLUME	NULL
97	NULL
,	NULL
NUMBER	NULL
11	NULL
plays	NULL
any	NULL
role	NULL
is	NULL
unclear	NULL
.	NULL

Our	NULL
data	NULL
using	NULL
a	NULL
distinct	NULL
syngeneic	NULL
leukemia	NULL
model	NULL
suggest	NULL
that	NULL
ectopic	NULL
ICSBP	NULL
expression	NULL
can	NULL
stimulate	NULL
a	NULL
CD8+*	NULL
cytotoxic	NULL
T-cell-mediated	NULL
antileukemia	NULL
immune	NULL
response	NULL
that	NULL
is	NULL
active	NULL
even	NULL
against	NULL
pre-established	NULL
disease	NULL
.	NULL

To	NULL
our	NULL
knowledge	NULL
,	NULL
this	NULL
represents	NULL
the	NULL
first	NULL
demonstration	NULL
that	NULL
expression	NULL
of	NULL
an	NULL
intracellular	NULL
transcriptional	NULL
regulator	NULL
,	NULL
rather	NULL
than	NULL
a	NULL
cell	NULL
surface	NULL
or	NULL
secreted	NULL
protein	NULL
,	NULL
can	NULL
elicit	NULL
a	NULL
protective	NULL
antileukemic	NULL
immune	NULL
response	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
Haiyan	NULL
Zhang	NULL
for	NULL
assistance	NULL
with	NULL
animal	NULL
care	NULL
and	NULL
Dr	NULL
Tomohiko	NULL
Tamura	NULL
and	NULL
Dr	NULL
Keiko	NULL
Ozato	NULL
for	NULL
providing	NULL
critical	NULL
reagents	NULL
,	NULL
including	NULL
the	NULL
ICSBP	NULL
cDNA	NULL
and	NULL
antibody	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
Professor	NULL
Herman	NULL
Eisen	NULL
for	NULL
critical	NULL
guidance	NULL
,	NULL
Carol	NULL
Mckinley	NULL
for	NULL
expert	NULL
technical	NULL
advice	NULL
on	NULL
the	NULL
cytotoxicity	NULL
assays	NULL
,	NULL
and	NULL
Herman	NULL
Eisen	NULL
,	NULL
Jianzhu	NULL
Chen	NULL
,	NULL
and	NULL
Eugene	NULL
Koh	NULL
for	NULL
discussions	NULL
and	NULL
critical	NULL
reading	NULL
of	NULL
the	NULL
manuscript	NULL
.	NULL

References	NULL
Sawyers	NULL
CL	NULL
.	NULL

Chronic	NULL
myeloid	NULL
leukemia	NULL
.	NULL

N	NULL
Eng	NULL
!	NULL

J	NULL
Med	NULL
.	NULL

1999	NULL
;	NULL
340:1330-1340.	NULL
elimination	NULL
of	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
.	NULL

Nat	NULL
Med	NULL
.	NULL

2000	NULL
;	NULL
6:1018-1023	NULL
.	NULL

..	NULL
Mamane	NULL
Y	NULL
,	NULL
Heyloroeck	NULL
C	NULL
,	NULL
Genin	NULL
P	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Inter	NULL
feron	NULL
regulatory	NULL
factors	NULL
:	NULL
the	NULL
next	NULL
generation	NULL
.	NULL

.	NULL

Matsuyama	NULL
T	NULL
,	NULL
Kimura	NULL
T	NULL
,	NULL
Kitagawa	NULL
M	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Tar	NULL
2	NULL
.	NULL

Guilhot	NULL
F	NULL
,	NULL
Lacotte-Thierry	NULL
L.	NULL
Interferon-alpha	NULL
:	NULL
13	NULL
mechanisms	NULL
of	NULL
action	NULL
in	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
in	NULL
chronic	NULL
phase	NULL
.	NULL

Hematol	NULL
Cell	NULL
Ther	NULL
.	NULL

Gene	NULL
.	NULL

1999	NULL
;	NULL
237:1-14	NULL
.	NULL

1998	NULL
;	NULL
40:237-239	NULL
.	NULL

14	NULL
3	NULL
.	NULL

Bhatia	NULL
R	NULL
,	NULL
Verfaillie	NULL
CM	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
interferon	NULL
alpha	NULL
on	NULL
beta-1	NULL
integrin	NULL
mediated	NULL
adhesion	NULL
and	NULL
growth	NULL
regulation	NULL
in	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
.	NULL

Leuk	NULL
Lymphoma	NULL
.	NULL

1998	NULL
;	NULL
28:241-254	NULL
.	NULL

Pane	NULL
F	NULL
,	NULL
Mostarda	NULL
1	NULL
,	NULL
Selleri	NULL
C	NULL
,	NULL
et	NULL
al	NULL
.	NULL

BCR/ABL	NULL
mRNA	NULL
and	NULL
the	NULL
P210	NULL
(	NULL
BCR/ABL	NULL
)	NULL
protein	NULL
are	NULL
downmodulated	NULL
by	NULL
interferon-alpha	NULL
in	NULL
chronic	NULL
myeloid	NULL
leukemia	NULL
patients	NULL
.	NULL

Blood	NULL
.	NULL

1999	NULL
;	NULL
94:2200-2207	NULL
.	NULL

Talpaz	NULL
M	NULL
,	NULL
Estrov	NULL
Z	NULL
,	NULL
Kantarjian	NULL
H	NULL
,	NULL
Ku	NULL
S	NULL
,	NULL
Foteh	NULL
A	NULL
,	NULL
Kurzrock	NULL
R.	NULL
Persistence	NULL
of	NULL
dormant	NULL
leukemic	NULL
progenitors	NULL
during	NULL
interferon-induced	NULL
remission	NULL
in	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
.	NULL

Analysis	NULL
by	NULL
polymerase	NULL
chain	NULL
reaction	NULL
of	NULL
individual	NULL
colonies	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
.	NULL

1994	NULL
;	NULL
94:1383-1389	NULL
.	NULL

Hochhaus	NULL
A	NULL
,	NULL
Lin	NULL
F	NULL
,	NULL
Reiter	NULL
A	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Variable	NULL
numbers	NULL
of	NULL
BCR-ABL	NULL
transcripts	NULL
persist	NULL
in	NULL
CML	NULL
pa	NULL
tients	NULL
who	NULL
achieve	NULL
complete	NULL
cytogenetic	NULL
remission	NULL
with	NULL
interferon-alpha	NULL
[	NULL
see	NULL
comments	NULL
]	NULL
.	NULL

Br	NULL
J	NULL
Haematol	NULL
.	NULL

1995	NULL
;	NULL
91:126-131.	NULL
.	NULL

Chomel	NULL
JC	NULL
,	NULL
Brizard	NULL
F	NULL
,	NULL
Veinstein	NULL
A	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Persis-	NULL
tence	NULL
of	NULL
BCR-ABL	NULL
genomic	NULL
rearrangement	NULL
in	NULL
chronic	NULL
myeloid	NULL
leukemia	NULL
patients	NULL
in	NULL
complete	NULL
and	NULL
sustained	NULL
cytogenetic	NULL
remission	NULL
after	NULL
interferon-alpha	NULL
therapy	NULL
or	NULL
allogeneic	NULL
bone	NULL
marrow	NULL
transplantation	NULL
.	NULL

Blood	NULL
.	NULL

2000	NULL
;	NULL
95:404-408.	NULL
.	NULL

Reiter	NULL
A	NULL
,	NULL
Marley	NULL
SB	NULL
,	NULL
Hochhaus	NULL
A	NULL
,	NULL
et	NULL
al	NULL
.	NULL

BCR	NULL
ABL-positive	NULL
progenitors	NULL
in	NULL
chronic	NULL
myeloid	NULL
leu-kaemia	NULL
patients	NULL
in	NULL
complete	NULL
cytogenetic	NULL
remission	NULL
after	NULL
treatment	NULL
with	NULL
interferon-alpha	NULL
.	NULL

Br	NULL
J	NULL
20.	NULL
geted	NULL
disruption	NULL
of	NULL
IRF-1	NULL
or	NULL
IRF-2	NULL
results	NULL
in	NULL
abnormal	NULL
type	NULL
|	NULL
IFN	NULL
gene	NULL
induction	NULL
and	NULL
aberrant	NULL
lymphocyte	NULL
development	NULL
.	NULL

Cell	NULL
.	NULL

1993	NULL
;	NULL
75:83-97.	NULL
.	NULL

Driggers	NULL
PH	NULL
,	NULL
Ennist	NULL
DL	NULL
,	NULL
Gleason	NULL
SL	NULL
,	NULL
et	NULL
a	NULL
.	NULL

An	NULL
in	NULL
terferon	NULL
gamma-regulated	NULL
protein	NULL
that	NULL
binds	NULL
the	NULL
interferon-inducible	NULL
enhancer	NULL
element	NULL
of	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
I	NULL
genes	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
U	NULL
S	NULL
A	NULL
.	NULL

1990	NULL
;	NULL
87:3743-3747	NULL
.	NULL

..	NULL
Weisz	NULL
A	NULL
,	NULL
Kirchhoff	NULL
S	NULL
,	NULL
Levi	NULL
BZ	NULL
.	NULL

IFN	NULL
consensus	NULL
sequence	NULL
binding	NULL
protein	NULL
(	NULL
ICSBP	NULL
)	NULL
is	NULL
a	NULL
conditional	NULL
repressor	NULL
of	NULL
IFN	NULL
inducible	NULL
promoters	NULL
.	NULL

Int	NULL
Immunol	NULL
.	NULL

1994	NULL
;	NULL
6:1125-1131.	NULL
.	NULL

Rehli	NULL
M	NULL
,	NULL
Poltorak	NULL
A	NULL
,	NULL
Schwarzfischer	NULL
L	NULL
,	NULL
Krause	NULL
SW	NULL
,	NULL
Andreesen	NULL
R	NULL
,	NULL
Beutler	NULL
B.	NULL
PU.1	NULL
and	NULL
interferon	NULL
consensus	NULL
sequence-binding	NULL
protein	NULL
regulate	NULL
the	NULL
myeloid	NULL
expression	NULL
of	NULL
the	NULL
human	NULL
Toll-like	NULL
receptor	NULL
4	NULL
gene	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
.	NULL

2000	NULL
;	NULL
275:9773-9781.	NULL
.	NULL

Eklund	NULL
EA	NULL
,	NULL
Kakar	NULL
R.	NULL
Recruitment	NULL
of	NULL
CREB-bind-	NULL
ing	NULL
protein	NULL
by	NULL
PU.1	NULL
,	NULL
IFN-regulatory	NULL
factor-1	NULL
,	NULL
and	NULL
the	NULL
IFN	NULL
consensus	NULL
sequence-binding	NULL
protein	NULL
is	NULL
necessary	NULL
for	NULL
IFN-gamma-induced	NULL
p67phox	NULL
and	NULL
gp91phox	NULL
expression	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

1999	NULL
;	NULL
163	NULL
:	NULL
6095-6105.	NULL
.	NULL

Contursi	NULL
C	NULL
,	NULL
Wang	NULL
IM	NULL
,	NULL
Gabriele	NULL
L	NULL
,	NULL
et	NULL
al	NULL
.	NULL

IFN	NULL
con	NULL
sensus	NULL
sequence	NULL
binding	NULL
protein	NULL
potentiates	NULL
STAT	NULL
1-dependent	NULL
activation	NULL
of	NULL
IENgamma-re-sponsive	NULL
promoters	NULL
in	NULL
macrophages	NULL
.	NULL

Proc	NULL
Nat	NULL
!	NULL

Acad	NULL
Sci	NULL
U	NULL
S	NULL
A	NULL
.	NULL

2000	NULL
;	NULL
97:91-96	NULL
.	NULL

Meraro	NULL
D	NULL
,	NULL
Hashmueli	NULL
S	NULL
,	NULL
Koren	NULL
B	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Protein-protein	NULL
and	NULL
DNA-protein	NULL
interactions	NULL
affect	NULL
the	NULL
25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

286	NULL
.	NULL

29	NULL
.	NULL

30.	NULL
feron	NULL
consensus	NULL
sequence	NULL
binding	NULL
protein	NULL
(	NULL
ICSBP	NULL
)	NULL
transcripts	NULL
in	NULL
human	NULL
myeloid	NULL
leukemias	NULL
.	NULL

Blood	NULL
.	NULL

1998	NULL
;	NULL
91:22-29	NULL
.	NULL

Hao	NULL
SX	NULL
,	NULL
Ren	NULL
R.	NULL
Expression	NULL
of	NULL
interferon	NULL
consensus	NULL
sequence	NULL
binding	NULL
protein	NULL
(	NULL
ICSBP	NULL
)	NULL
is	NULL
down-regulated	NULL
in	NULL
Ber-Abl-induced	NULL
murine	NULL
chronic	NULL
myelogenous	NULL
leukemia-like	NULL
disease	NULL
,	NULL
and	NULL
forced	NULL
coexpression	NULL
of	NULL
ICSBP	NULL
inhibits	NULL
Ber-Abl-induced	NULL
myeloproliferative	NULL
disorder	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
.	NULL

2000	NULL
;	NULL
20:1149-1161	NULL
.	NULL

Tamura	NULL
T	NULL
,	NULL
Nagamura-Inoue	NULL
T	NULL
,	NULL
Shmeltzer	NULL
Z	NULL
,	NULL
Ku-wata	NULL
T	NULL
,	NULL
Ozato	NULL
K.	NULL
ICSBP	NULL
directs	NULL
bipotential	NULL
myeloid	NULL
progenitor	NULL
cells	NULL
to	NULL
differentiate	NULL
into	NULL
mature	NULL
macrophages	NULL
.	NULL

Immunity	NULL
.	NULL

2000	NULL
;	NULL
13:155-165	NULL
.	NULL

Scharton-Kersten	NULL
T	NULL
,	NULL
Contursi	NULL
C	NULL
,	NULL
Masumi	NULL
A	NULL
,	NULL
Sher	NULL
A	NULL
,	NULL
Ozato	NULL
K.	NULL
Interferon	NULL
consensus	NULL
sequence	NULL
binding	NULL
protein-deficient	NULL
mice	NULL
display	NULL
impaired	NULL
resistance	NULL
to	NULL
intracellular	NULL
infection	NULL
due	NULL
to	NULL
a	NULL
primary	NULL
defect	NULL
in	NULL
interleukin	NULL
12	NULL
p40	NULL
induction	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
.	NULL

1997	NULL
;	NULL
186:1523-1534	NULL
.	NULL

Giese	NULL
NA	NULL
,	NULL
Gabriele	NULL
L	NULL
,	NULL
Doherty	NULL
TM	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Interferon	NULL
(	NULL
IFN	NULL
)	NULL
consensus	NULL
sequence-binding	NULL
protein	NULL
,	NULL
a	NULL
transcription	NULL
factor	NULL
of	NULL
the	NULL
IFN	NULL
regulatory	NULL
factor	NULL
family	NULL
,	NULL
regulates	NULL
immune	NULL
responses	NULL
in	NULL
vivo	NULL
through	NULL
control	NULL
of	NULL
interleukin	NULL
12	NULL
expression	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
.	NULL

1997	NULL
;	NULL
186:1535-1546	NULL
.	NULL

Wang	NULL
IM	NULL
,	NULL
Contursi	NULL
C	NULL
,	NULL
Masumi	NULL
A	NULL
,	NULL
Ma	NULL
X	NULL
,	NULL
Trinchieri	NULL
G	NULL
,	NULL
Ozato	NULL
K.	NULL
An	NULL
IFN-gamma-inducible	NULL
transcription	NULL
factor	NULL
,	NULL
IFN	NULL
consensus	NULL
sequence	NULL
binding	NULL
protein	NULL
(	NULL
ICSBP	NULL
)	NULL
,	NULL
stimulates	NULL
IL-12	NULL
p40	NULL
expression	NULL
in	NULL
macrophages	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

2000	NULL
;	NULL
165:271-279	NULL
.	NULL

Palacios	NULL
R	NULL
,	NULL
Steinmetz	NULL
M.	NULL
II-3-dependent	NULL
mouse	NULL
clones	NULL
that	NULL
express	NULL
B-220	NULL
surface	NULL
antigen	NULL
,	NULL
contain	NULL
Ig	NULL
genes	NULL
in	NULL
germ-line	NULL
configuration	NULL
,	NULL
and	NULL
generate	NULL
B	NULL
lymphocytes	NULL
in	NULL
vivo	NULL
.	NULL

Cell	NULL
.	NULL

1985	NULL
;	NULL
41:727-734	NULL
.	NULL

Haematol	NULL
.	NULL

1998	NULL
;	NULL
102:1271-1278.	NULL
activity	NULL
of	NULL
lymphoid-specific	NULL
IFN	NULL
regulatory	NULL
fac-	NULL
31.	NULL
railwnfeTtiL—izl	NULL
$	NULL
6,322	NULL
:	NULL
Essstiéiioaig	NULL
}	NULL
m¥	NULL
$	NULL
;	NULL
prlsz—	NULL
9	NULL
.	NULL

Gardiner	NULL
N	NULL
,	NULL
Lawler	NULL
M	NULL
,	NULL
O'Riordan	NULL
J	NULL
,	NULL
DeArce	NULL
M	NULL
,	NULL
tors	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

1999	NULL
;	NULL
163:6468-6478.	NULL
lignant	NULL
transformation	NULL
of	NULL
interleukin-3-dependent	NULL
Humphries	NULL
P	NULL
,	NULL
McCann	NULL
SR	NULL
.	NULL

Persistent	NULL
donor	NULL
chi-	NULL
21	NULL
.	NULL

Holtschke	NULL
T	NULL
,	NULL
Lohler	NULL
J	NULL
,	NULL
Kanno	NULL
Y	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Immunodefi-	NULL
32D	NULL
hematopoietic	NULL
cells	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
.	NULL

1999	NULL
;	NULL
19	NULL
:	NULL
maerism	NULL
is	NULL
consistent	NULL
with	NULL
disease-free	NULL
survival	NULL
ciency	NULL
and	NULL
chronic	NULL
myelogenous	NULL
leukemia-like	NULL
7995-8002.	NULL
following	NULL
BMT	NULL
for	NULL
chronic	NULL
myeloid	NULL
leukaemia	NULL
.	NULL

syndrome	NULL
in	NULL
mice	NULL
with	NULL
a	NULL
targeted	NULL
mutation	NULL
of	NULL
the	NULL
32	NULL
.	NULL

Chambaud	NULL
I.	NULL
Wroblewski	NULL
H.	NULL
Blanchard	NULL
A.	NULL
Interac-Bone	NULL
Marrow	NULL
Transplant	NULL
.	NULL

1997	NULL
;	NULL
20:235-241	NULL
.	NULL

ICSBP	NULL
gene	NULL
.	NULL

Cell	NULL
.	NULL

1996	NULL
;	NULL
87:307-317.	NULL
tions	NULL
betwee	NULL
,	NULL
n	NULL
mycoplasma'lipoproteins	NULL
and	NULL
the	NULL
10	NULL
.	NULL

Pawelec	NULL
G	NULL
,	NULL
Da	NULL
Silva	NULL
P	NULL
,	NULL
Max	NULL
H	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Relative	NULL
22	NULL
.	NULL

Gabriele	NULL
L	NULL
,	NULL
Phung	NULL
J	NULL
,	NULL
Fukumoto	NULL
J	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Regula-	NULL
host	NULL
immune	NULL
system	NULL
.	NULL

Trends	NULL
Microbiol	NULL
.	NULL

1999	NULL
;	NULL
7	NULL
:	NULL
roles	NULL
of	NULL
natural	NULL
killer-	NULL
and	NULL
T	NULL
cell-mediated	NULL
anti-	NULL
tion	NULL
of	NULL
apoptosis	NULL
in	NULL
myeloid	NULL
cells	NULL
by	NULL
interferon	NULL
493-499.	NULL
leukemia	NULL
effects	NULL
in	NULL
chronic	NULL
myelogenous	NULL
leuke-	NULL
consensus	NULL
sequence-binding	NULL
protein	NULL
[	NULL
published	NULL
33	NULL
.	NULL

Sykulev	NULL
Y	NULL
,	NULL
Vugmeyster	NULL
Y	NULL
,	NULL
Brunmark	NULL
A	NULL
,	NULL
Ploegh	NULL
mia	NULL
patients	NULL
treated	NULL
with	NULL
interferon-alpha	NULL
.	NULL

Leuk	NULL
erratum	NULL
appears	NULL
in	NULL
J	NULL
Exp	NULL
Med	NULL
.	NULL

1999	NULL
;	NULL
190:1722	NULL
]	NULL
.	NULL

HL	NULL
,	NULL
Eisen	NULL
HN	NULL
.	NULL

Peptide	NULL
antagonism	NULL
and	NULL
T	NULL
cell	NULL
re-Lymphoma	NULL
.	NULL

1995	NULL
;	NULL
18:471-478	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
.	NULL

1999	NULL
;	NULL
190:411-421.	NULL
ceptor	NULL
interactions	NULL
with	NULL
peptide-MHC	NULL
complexes	NULL
.	NULL

11	NULL
.	NULL

Oka	NULL
T	NULL
,	NULL
Sastry	NULL
KJ	NULL
,	NULL
Nehete	NULL
P	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Evidence	NULL
for	NULL
23	NULL
.	NULL

Scheller	NULL
M	NULL
,	NULL
Foerster	NULL
J	NULL
,	NULL
Heyworth	NULL
CM	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Al-	NULL
Immunity	NULL
.	NULL

1998	NULL
;	NULL
9:475-483.	NULL
specific	NULL
immune	NULL
response	NULL
against	NULL
P210	NULL
BCR-	NULL
tered	NULL
development	NULL
and	NULL
cytokine	NULL
responses	NULL
of	NULL
34	NULL
.	NULL

Daley	NULL
GQ	NULL
,	NULL
Baltimore	NULL
D.	NULL
Transformation	NULL
of	NULL
an	NULL
in-ABL	NULL
in	NULL
long-term	NULL
remission	NULL
CML	NULL
patients	NULL
treated	NULL
myeloid	NULL
progenitors	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
transcrip-	NULL
terleukin	NULL
3-dependent	NULL
hematopoietic	NULL
cell	NULL
line	NULL
by	NULL
with	NULL
interferon	NULL
.	NULL

Leukemia	NULL
.	NULL

1998	NULL
;	NULL
12:155-163.	NULL
tion	NULL
factor	NULL
,	NULL
interferon	NULL
consensus	NULL
sequence	NULL
bind-	NULL
the	NULL
chronic	NULL
myelogenous	NULL
leukemia-specific	NULL
12	NULL
.	NULL

Molidrem	NULL
JJ	NULL
,	NULL
Lee	NULL
PP	NULL
,	NULL
Wang	NULL
C	NULL
,	NULL
etal	NULL
.	NULL

Evidence	NULL
ing	NULL
protein	NULL
.	NULL

Blood	NULL
.	NULL

1999	NULL
;	NULL
94:3764-3771	NULL
.	NULL

P21	NULL
Ober/abl	NULL
protein	NULL
.	NULL

Proc	NULL
Nat	NULL
!	NULL

Acad	NULL
Sci	NULL
U	NULL
SA	NULL
.	NULL

that	NULL
specific	NULL
T	NULL
lymphocytes	NULL
may	NULL
participate	NULL
in	NULL
the	NULL
24	NULL
.	NULL

Schmidt	NULL
M	NULL
,	NULL
Nagel	NULL
!	NULL

S	NULL
,	NULL
Proba	NULL
J	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Lack	NULL
of	NULL
inter-	NULL
1988	NULL
;	NULL
85:9312-9316	NULL
.	NULL

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

BLOOD	NULL
,	NULL
1	NULL
JUNE	NULL
2001	NULL
«	NULL
VOLUME	NULL
97	NULL
,	NULL
NUMBER	NULL
11	NULL
35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

Shultz	NULL
LD	NULL
,	NULL
Schweitzer	NULL
PA	NULL
,	NULL
Christianson	NULL
SW	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Multiple	NULL
defects	NULL
in	NULL
innate	NULL
and	NULL
adaptive	NULL
immunologic	NULL
function	NULL
in	NULL
NOD/LtSz-scid	NULL
mice	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

1995	NULL
;	NULL
154:180-191	NULL
.	NULL

Mombaerts	NULL
P	NULL
,	NULL
lacomini	NULL
J	NULL
,	NULL
Johnson	NULL
RS	NULL
,	NULL
Herrup	NULL
K	NULL
,	NULL
Tonegawa	NULL
S	NULL
,	NULL
Papaioannou	NULL
VE	NULL
.	NULL

RAG-1-deficient	NULL
mice	NULL
have	NULL
no	NULL
mature	NULL
B	NULL
and	NULL
T	NULL
lymphocytes	NULL
.	NULL

Cell	NULL
.	NULL

1992	NULL
;	NULL
68:869-877	NULL
.	NULL

Ashwell	NULL
JD	NULL
,	NULL
Jenkins	NULL
MK	NULL
,	NULL
Schwartz	NULL
RH	NULL
.	NULL

Effect	NULL
of	NULL
gamma	NULL
radiation	NULL
on	NULL
resting	NULL
B	NULL
lymphocytes	NULL
,	NULL
II	NULL
:	NULL
functional	NULL
characterization	NULL
of	NULL
the	NULL
antigen-presen-tation	NULL
defect	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

1988	NULL
;	NULL
141:2536-2544	NULL
.	NULL

Barrett	NULL
AJ	NULL
.	NULL

Mechanisms	NULL
of	NULL
the	NULL
graft-versus-leukemia	NULL
reaction	NULL
.	NULL

Stem	NULL
Cells	NULL
.	NULL

1997	NULL
;	NULL
15:248-258	NULL
.	NULL

Pinilla-lbarz	NULL
J	NULL
,	NULL
Cathcart	NULL
K	NULL
,	NULL
Korontsvit	NULL
T	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Vaccination	NULL
of	NULL
patients	NULL
with	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
with	NULL
ber-abl	NULL
oncogene	NULL
breakpoint	NULL
fusion	NULL
40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

ICSBP-INDUCED	NULL
IMMUNITY	NULL
AGAINST	NULL
BCR/ABL+®	NULL
LEUKEMIA	NULL
peptides	NULL
generates	NULL
specific	NULL
immune	NULL
responses	NULL
.	NULL

Blood	NULL
.	NULL

2000	NULL
;	NULL
95:1781-1787	NULL
.	NULL

Pinilla-lbarz	NULL
J	NULL
,	NULL
Cathcart	NULL
K	NULL
,	NULL
Scheinberg	NULL
DA	NULL
.	NULL

CML	NULL
vaccines	NULL
as	NULL
a	NULL
paradigm	NULL
of	NULL
the	NULL
specific	NULL
immunotherapy	NULL
of	NULL
cancer	NULL
.	NULL

Blood	NULL
Rev	NULL
.	NULL

2000	NULL
;	NULL
14:111-120	NULL
.	NULL

Nelson	NULL
N	NULL
,	NULL
Marks	NULL
MS	NULL
,	NULL
Driggers	NULL
PH	NULL
,	NULL
Ozato	NULL
K.	NULL
Interferon	NULL
consensus	NULL
sequence-binding	NULL
protein	NULL
,	NULL
a	NULL
member	NULL
of	NULL
the	NULL
interferon	NULL
regulatory	NULL
factor	NULL
family	NULL
,	NULL
suppresses	NULL
interferon-induced	NULL
gene	NULL
transcrip-tion	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
.	NULL

1993	NULL
;	NULL
13:588-599	NULL
.	NULL

Matulonis	NULL
UA	NULL
,	NULL
Dosiou	NULL
C	NULL
,	NULL
Lamont	NULL
C	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Role	NULL
of	NULL
B7-1	NULL
in	NULL
mediating	NULL
an	NULL
immune	NULL
response	NULL
to	NULL
myeloid	NULL
leukemia	NULL
cells	NULL
.	NULL

Blood	NULL
.	NULL

1995	NULL
;	NULL
85:2507-2515	NULL
.	NULL

Dunussi-Joannopoulos	NULL
K	NULL
,	NULL
Runyon	NULL
K	NULL
,	NULL
Erickson	NULL
J	NULL
,	NULL
Schaub	NULL
RG	NULL
,	NULL
Hawley	NULL
RG	NULL
,	NULL
Leonard	NULL
JP	NULL
.	NULL

Vaccines	NULL
with	NULL
interleukin-12-transduced	NULL
acute	NULL
myeloid	NULL
leukemia	NULL
cells	NULL
elicit	NULL
very	NULL
potent	NULL
therapeutic	NULL
and	NULL
44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

3497	NULL
long-lasting	NULL
protective	NULL
immunity	NULL
.	NULL

Blood	NULL
.	NULL

1999	NULL
;	NULL
94	NULL
;	NULL
4263-4273	NULL
.	NULL

Boehm	NULL
U	NULL
,	NULL
Klamp	NULL
T	NULL
,	NULL
Groot	NULL
M	NULL
,	NULL
Howard	NULL
JC	NULL
.	NULL

Cellular	NULL
responses	NULL
to	NULL
interferon-gamma	NULL
.	NULL

Annu	NULL
Rev	NULL
Immunol	NULL
.	NULL

1997	NULL
;	NULL
15:749-795	NULL
.	NULL

Wang	NULL
IM	NULL
,	NULL
Contursi	NULL
C	NULL
,	NULL
Masumi	NULL
A	NULL
,	NULL
Ma	NULL
X	NULL
,	NULL
Trinchieri	NULL
G	NULL
,	NULL
Ozato	NULL
K.	NULL
An	NULL
IFN-gamma-inducible	NULL
transcription	NULL
factor	NULL
,	NULL
IFN	NULL
consensus	NULL
sequence	NULL
binding	NULL
protein	NULL
(	NULL
ICSBP	NULL
)	NULL
,	NULL
stimulates	NULL
IL-12	NULL
p40	NULL
expression	NULL
in	NULL
macrophages	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

2000	NULL
;	NULL
165:271-279	NULL
.	NULL

Dranoff	NULL
G	NULL
,	NULL
Jaffee	NULL
E	NULL
,	NULL
Lazenby	NULL
A	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Vaccination	NULL
with	NULL
irradiated	NULL
turnor	NULL
cells	NULL
engineered	NULL
to	NULL
secrete	NULL
murine	NULL
granulocyte-macrophage	NULL
colony	NULL
ing	NULL
factor	NULL
stimulates	NULL
potent	NULL
,	NULL
specific	NULL
,	NULL
and	NULL
long-lasting	NULL
anti-tumor	NULL
immunity	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
U	NULL
S	NULL
A	NULL
.	NULL

1993	NULL
;	NULL
90:3539-3543	NULL
.	NULL

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

®	NULL
2001	NULL
97	NULL
:	NULL
3491-3497	NULL
doi:10.1182/blood.V97.11.3491	NULL
Expression	NULL
of	NULL
interferon	NULL
consensus	NULL
sequence	NULL
binding	NULL
protein	NULL
induces	NULL
potent	NULL
immunity	NULL
against	NULL
BCR/ABL-induced	NULL
leukemia	NULL
Ming	NULL
Deng	NULL
and	NULL
George	NULL
Q.	NULL
Daley	NULL
A	NULL
TY	NULL
O	NULL
0C	NULL
,	NULL
f	NULL
ghURIC	NULL
ANA	NULL
a	NULL
'	NULL
%	NULL
:	NULL
r	NULL
)	NULL
...	NULL
3\	NULL
®	NULL
``	NULL
Pion	NULL
(	NULL
@	NULL
0	NULL
Updated	NULL
information	NULL
and	NULL
services	NULL
can	NULL
be	NULL
found	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/content/97/11/3491	NULL
.full.html	NULL
Articles	NULL
on	NULL
similar	NULL
topics	NULL
can	NULL
be	NULL
found	NULL
in	NULL
the	NULL
following	NULL
Blood	NULL
collections	NULL
Immunobiology	NULL
and	NULL
Immunotherapy	NULL
(	NULL
5674	NULL
articles	NULL
)	NULL
Neoplasia	NULL
(	NULL
4182	NULL
articles	NULL
)	NULL
Signal	NULL
Transduction	NULL
(	NULL
1930	NULL
articles	NULL
)	NULL
Information	NULL
about	NULL
reproducing	NULL
this	NULL
article	NULL
in	NULL
parts	NULL
or	NULL
in	NULL
its	NULL
entirety	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
requests	NULL
Information	NULL
about	NULL
ordering	NULL
reprints	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/misc/rights.xhtml	NULL
#	NULL
reprints	NULL
Information	NULL
about	NULL
subscriptions	NULL
and	NULL
ASH	NULL
membership	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/subscriptions/index.xhtml	NULL
Blood	NULL
(	NULL
print	NULL
ISSN	NULL
0006-4971	NULL
,	NULL
online	NULL
ISSN	NULL
1528-0020	NULL
)	NULL
,	NULL
is	NULL
published	NULL
weekly	NULL
by	NULL
the	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
,	NULL
2021	NULL
L	NULL
St	NULL
,	NULL
NW	NULL
,	NULL
Suite	NULL
900	NULL
,	NULL
Washington	NULL
DC	NULL
20036	NULL
.	NULL

Copyright	NULL
2011	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
;	NULL
all	NULL
rights	NULL
reserved	NULL
.	NULL

